On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize Parkinson disease (PD) as a multisystem alpha-synucleinopathy characterized by the progressive loss of dopaminergic neurons, leading to both classic motor deficits and a wide array of non-motor symptoms (NMS).
- •Identify the clinical phases of the disease, starting with a prodromal phase (hyposmia, constipation, REM sleep behavior disorder) that can precede motor onset by decades, followed by early-stage responsiveness to therapy and late-stage motor complications like (FOG).
- •Understand the shifting diagnostic paradigm toward the SynNeurGe framework, which classifies the disease based on α-synuclein (S), neurodegeneration (N), and genetics (G) rather than purely clinical phenomenology.
- •Note the demographic trends where PD disproportionately affects males (2:1 ratio) and is increasingly prevalent in aging populations, though early-onset Parkinson disease (EOPD) affects those aged 21–50 and often carries a higher genetic burden.
- •Distinguish idiopathic PD from 'Parkinson-plus' syndromes such as (MSA) and (PSP), which typically present with more rapid progression and poor levodopa response.
Evaluation
- •Suspect PD in any patient presenting with asymmetric motor signs, particularly a 4–6 Hz 'pill-rolling' rest tremor, lead-pipe or cogwheel rigidity, or unexplained slowness in activities of daily living.
- •Confirm the presence of bradykinesia, the essential motor sign, by observing a decrement in amplitude or speed during repetitive movements such as finger tapping or rapid alternating hand movements.
- •Perform a Levodopa Challenge by administering a suprathreshold dose (typically 200 mg of levodopa) and measuring the MDS-UPDRS Part III score; a >30% improvement in motor function strongly supports an idiopathic PD diagnosis.
- •Identify 'red flags' that suggest alternative diagnoses, including early severe autonomic failure (orthostatic hypotension), vertical supranuclear gaze palsy, or falls occurring within the first three years of symptom onset.
- •Screen for non-motor features during the clinical encounter, specifically asking about hyposmia (loss of smell), REM sleep behavior disorder (acting out dreams), and chronic constipation.
- •Order a structural MRI to rule out secondary causes such as normal pressure hydrocephalus or vascular , though conventional imaging is often normal in early idiopathic PD.
- •Utilize DaTscan ([123I]FP-CIT SPECT) in cases of clinical uncertainty to visualize striatal dopamine transporter density and confirm a presynaptic dopaminergic deficit.
- •Consider a skin biopsy to detect S129 phospho-α-synuclein (pαSyn) at the C7 and Th12 dermatomes, which can highly accurately differentiate synucleinopathies from tauopathies like PSP.
- •Assess gait and balance using dual-task challenges (e.g., walking while performing mental arithmetic) to reveal impaired motor automaticity and the risk of .
- •Monitor orthostatic blood pressure trajectories longitudinally, as early autonomic failure is a marker for faster disease progression and increased vascular risk.
- •Evaluate for impulse control disorders (ICD) such as pathological gambling or hypersexuality, particularly in patients already receiving dopamine agonist therapy.
Management
- •Administer Carbidopa-Levodopa (e.g., 25/100 mg TID) as the gold standard for motor symptom control, ensuring strict adherence to dosing schedules to avoid 'off' periods.
- •Prioritize medication timing in hospitalized patients; delays or omissions of dopaminergic doses are associated with increased morbidity and mortality in the inpatient setting.
- •Manage 'wearing-off' fluctuations by adding adjunctive therapies such as COMT inhibitors, MAO-B inhibitors, or Amantadine-IR 200 mg/day to reduce peak-dose dyskinesia.
- •Prescribe a cycling exercise protocol (40-60 minutes, 3 times per week) to improve movement vigor and significantly reduce the progression of urinary frequency.
- •Implement High-Intensity Expiratory Muscle Strength Training (EMST) at 60% of maximal expiratory pressure to improve swallowing safety and prevent .
- •Refer for bilateral subthalamic nucleus (STN) (DBS) in patients with advanced PD who experience medication-refractory motor fluctuations but remain levodopa-responsive.
- •Utilize non-invasive neuromodulation such as transcutaneous auricular vagus nerve stimulation (taVNS) to improve gait parameters and sleep quality.
- •Treat mild-to-moderate depressive symptoms with High-Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting the left dorsolateral prefrontal cortex.
- •Address postural deformities like camptocormia using wearable sensor-based braces that provide vibratory feedback when forward flexion exceeds a pre-set threshold.
- •Manage chronic constipation using the '6S' model, emphasizing high fiber intake and standardized laxative protocols.
- •Screen for and manage bone health by performing a baseline DXA scan at diagnosis and initiating Vitamin D and Calcium supplementation to prevent fragility fractures.
- •Avoid typical antipsychotics (e.g., Haloperidol) and certain antiemetics (e.g., Metoclopramide) as they can severely exacerbate parkinsonian motor symptoms.
- •Consider Donor (dFMT) in drug-naïve patients to improve both motor and gastrointestinal symptoms via the gut-brain axis.
- •Transition to Continuous Subcutaneous Apomorphine Infusion (CSAI) in advanced stages if the oral route is compromised by severe or terminal illness.
- •Provide genetic counseling for patients with GBA1 or LRRK2 variants, focusing on variable penetrance and the implications for family members.
Board Review — High Yield
- •Lewy Bodies — Pathognomonic intracellular aggregates of misfolded alpha-synuclein.
- •Bradykinesia — The essential clinical feature required for diagnosis; characterized by slowness and decrement in amplitude.
- •RBD (REM Sleep Behavior Disorder) — A highly specific prodromal marker for future synucleinopathy development.
- •GBA1 Mutation — The most common genetic risk factor for Parkinson disease.
- •Micrographia — A classic clinical sign where handwriting becomes progressively smaller and cramped.
- •Pill-rolling tremor — A 4–6 Hz resting tremor that typically disappears with purposeful movement.
- •Honeymoon Period — The initial years of treatment where patients have a robust and stable response to levodopa.
- •Freezing of Gait — An episodic 'glued to the floor' sensation, often triggered by doorways or turning.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Parkinson disease (PD) and Parkinson’s disease are interchangeable names used in the cited literature.[213][214][215][216][219]
- ▸PD is a heterogeneous neurodegenerative condition with motor and non-motor manifestations.[213][214][220]
- ▸Alpha-synucleinopathies include PD, DLB, MSA, and PAF; these are related classifications, not synonyms.[4]
- ▸Isolated or idiopathic REM sleep behavior disorder is a prodromal state that may precede clinically diagnosed PD, DLB, or MSA.[216]
- ▸Parkinson disease dementia and Parkinson disease with mild cognitive impairment are associated cognitive classifications rather than synonyms for PD.[218][222]
- ▸Surveillance definitions may use hospital diagnoses, medication prescriptions, or combined data sources and may not be interchangeable with specialist clinical criteria.[7][215]
Definition
Parkinson disease (PD), also written Parkinson’s disease, is a clinically defined neurodegenerative condition characterized by motor and non-motor manifestations and substantial variability in symptom profile, progression, and treatment response.[220] The supplied literature uses “Parkinson disease,” “Parkinson’s disease,” and the abbreviation “PD” as equivalent labels for the condition.[213]C[214][215][216]C[218][219][220][222][223][224]C In research and surveillance, however, the label does not always represent an identical diagnostic construct: studies have used clinical diagnoses, specialist assessments, registry records, medication prescriptions, and combinations of these sources to identify PD.[215][219]
PD is not limited to motor impairment. The cited studies identify anxiety, depression, executive dysfunction, cognitive impairment, fatigue, autonomic dysfunction, falls, and sleep-related phenomena among manifestations or clinically relevant correlates of PD.[213]C[214][216]C[3][4][218][222][223] Motor asymmetry is described as a characteristic feature, although its definition and clinical implications may vary according to the scoring method used.[29]D Large-scale brain-network disruption and individual differences in functional connectivity have also been investigated as features of the disorder, but these research measures are not presented as standalone diagnostic definitions.[220]
Synonyms and related terminology
- Parkinson disease (PD): The preferred disease name used throughout the cited clinical and epidemiologic literature.[213]C[215][219]
- Parkinson’s disease: A possessive spelling used interchangeably with “Parkinson disease” in article titles and abstracts.[214][216]C[3][7][222][223][224]C
- Idiopathic PD: A designation used in a randomized study to identify adults with mild-to-moderate disease without a stated secondary cause.[6]
- Parkinson disease dementia (PDD): A cognitive disorder associated with PD and discussed as a later clinical outcome or diagnostic category rather than as a synonym for PD.[218] Diagnostic algorithms for PDD may use screening criteria, functional assessment, and neuropsychological testing; the cited study evaluated concordance among 68 operationalized algorithms in 190 people with PD.[218]
- Alpha-synucleinopathy: A broader disease grouping that includes PD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF).[4] PD therefore represents one member of the alpha-synucleinopathy spectrum, but the related disorders are not synonyms for PD.[4]
- Prodromal synucleinopathy: A prediagnostic state in which early manifestations may precede clinically diagnosed PD, DLB, or MSA.[216]C Polysomnography-confirmed isolated or idiopathic rapid-eye-movement sleep behavior disorder (iRBD) is used as a prodromal cohort state for studying evolution toward these clinically diagnosed diseases.[216]C
Classification
A practical classification should separate clinical PD, prodromal disease, associated cognitive syndromes, and broader synucleinopathies. Clinical PD refers to the diagnosed disorder studied in neurology, intervention, observational, and epidemiologic cohorts.[213]C[214][215][220] “Idiopathic” or “isolated” PD is used when the study population is specifically restricted to patients described as having idiopathic disease.[6]
PD may also be classified by clinical domain. Motor classification can include appendicular motor severity, motor asymmetry, axial symptoms, falls risk, and treatment state; asymmetry has been quantified as the difference between right- and left-sided appendicular MDS-UPDRS III scores, with normalized asymmetry additionally adjusted for global motor severity.[29]D Non-motor classification includes neuropsychiatric symptoms, executive dysfunction, cognitive impairment, fatigue, autonomic blood-pressure abnormalities, and sleep-related symptoms.[213]C[214][4][216]C[222][223] These domains describe phenotype and burden rather than separate diseases.[213]C[214][222][223]
Cognitive status provides an important associated classification. Parkinson disease with mild cognitive impairment is recognized in the cited literature as a clinically important state that may be screened using Montreal Cognitive Assessment-based Movement Disorder Society Level I labels and evaluated more comprehensively with Level II neuropsychological testing.[222] Parkinson disease dementia represents a more advanced or distinct cognitive diagnostic category requiring consideration of cognitive and functional criteria; proposed algorithms differ in screening tests and breadth of functional assessment.[218]
For epidemiologic surveillance, PD may be operationally defined using a single or combined data source. The NNCSS systematic review evaluated case definitions and data sources intended to generate population-based estimates.[215] One nationwide Danish cohort defined incident PD as either a first hospital contact with PD as the primary diagnosis or a redeemed prescription for PD medication in national registries.[7] Such operational definitions are useful for surveillance but may differ from specialist clinical criteria and should not be assumed to be interchangeable.[7][215]
Finally, biomarker-based classification is emerging but should not replace the clinical disease label without appropriate validation. Cerebrospinal-fluid alpha-synuclein seed amplification assays detect Lewy-body pathology and have been evaluated against clinical diagnoses in routine clinical samples, including patients with diverse neurologic and psychiatric conditions.[27]D The supplied evidence supports use of this assay as an investigational or adjunctive classification tool, not as a universally sufficient definition of PD.[27]D
Scope and limitations
The cited evidence demonstrates that PD is a heterogeneous clinical syndrome with motor, non-motor, cognitive, autonomic, and prodromal dimensions.[213]C[214][216]C[220][222][223] It also shows that the apparent frequency and classification of PD depend on the case definition, data source, clinical setting, and diagnostic threshold applied.[7][215] The references do not establish a single universally applicable molecular, imaging, or administrative definition that independently captures every patient with PD.[215][220][27]D
| Category | Terms or examples | Interpretation |
|---|---|---|
| Disease name | Parkinson disease; Parkinson’s disease; PD | Equivalent labels in the cited literature.[213]C[214][215] |
| Clinical subtype designation | Idiopathic PD | Used for selected cohorts described as having idiopathic disease.[6] |
| Prodromal state | Isolated/idiopathic RBD; prodromal synucleinopathy | Prediagnostic state associated with later PD, DLB, or MSA.[216]C |
| Cognitive classification | PD with mild cognitive impairment; PDD | Associated cognitive states requiring cognitive and, for PDD, functional assessment.[218][222] |
| Broader pathology group | Alpha-synucleinopathies | Includes PD, DLB, MSA, and PAF.[4] |
| Surveillance construct | Registry diagnosis; medication-based definition | Operational definitions used for population estimates, not necessarily equivalent to clinical criteria.[7][215] |
| Biomarker construct | CSF αSyn-SAA status | Adjunctive detection of Lewy-body pathology under clinical evaluation.[27]D |
Epidemiology and Risk Factors
- ▸PD prevalence increased significantly in nationwide Swedish and French analyses spanning **2003–2022**, although the supplied evidence does not quantify the contributions of incidence versus survival. [239]
- ▸Diabetes mellitus is recognized as a PD risk factor; clinically diagnosed type 1 diabetes was associated with higher PD risk in Korea (adjusted odds ratio **1.42**, 95% CI 1.06–1.90). [228][243]
- ▸TBI is a potential but not proven causal risk factor; current evidence includes Mexican cross-sectional data, a US Veterans retrospective cohort, and a Korean study of motor phenotype. [237][240][241]
- ▸Cholesterol and LDL-C associations with PD risk and progression remain biologically plausible but inconsistent and unresolved. [230]
- ▸Pure autonomic failure is a possible prodromal presentation of PD and other central α-synucleinopathies. [231]
- ▸Brain-first and body-first models describe potentially distinct routes of α-synuclein propagation and may contribute to clinical and epidemiologic heterogeneity. [236]
Parkinson disease (PD) is a progressive neurodegenerative disorder whose occurrence reflects interacting genetic, metabolic, environmental, and age-related factors; the available 2026 evidence also emphasizes substantial biological heterogeneity rather than a single disease pathway. [225][230][236][238]
Epidemiology and temporal trends
Population-level prevalence of PD increased significantly in nationwide Swedish and French studies covering 2003–2022. The investigators evaluated whether rising prevalence resulted from increasing incidence, improved survival, or both, using age- and sex-standardized measures, incidence, age at diagnosis, and life expectancy. [239] These findings support a continuing increase in the population burden of PD, although the supplied abstract does not provide the corresponding country-specific effect estimates or quantify the relative contributions of incidence and survival. [239]
Accurate epidemiologic classification remains challenging because clinical features overlap among parkinsonian disorders, pathognomonic manifestations may emerge late, and in-vivo biomarkers are limited. An autopsy-confirmed, multi-ancestry brain-bank cohort from the United Kingdom, United States, and Australia therefore provides important context for interpreting reported PD prevalence and genetic associations, while also highlighting potential differences between clinical diagnoses and underlying pathology. [238]
Age, sex, and clinical heterogeneity
The references do not provide a new pooled estimate of age-specific or sex-specific PD incidence. However, several studies incorporated age and sex because these variables may modify observed associations. The antidiabetic-medication network meta-analysis prespecified subgroup analyses by age, sex, and cardiovascular-disease status, indicating that the relationship between diabetes treatment and PD risk may not be uniform across populations. [228] A Mexican multicenter study specifically examined sex-related differences in the association between cumulative traumatic brain injury (TBI) and PD. [240]
PD may comprise biologically distinct “brain-first” and “body-first” phenotypes. A systematic review described a central-nervous-system-initiated pathway (“brain-first”) and a bottom-up pathway (“body-first”), both framed around possible patterns of α-synuclein propagation. [236] This model is clinically relevant to epidemiology because differences in prodromal symptoms, biomarkers, and disease progression could influence case ascertainment and apparent risk-factor associations. [236]
Metabolic and vascular factors
Diabetes mellitus is recognized as a risk factor for PD in the comparative antidiabetic-treatment literature. [228] A Bayesian network meta-analysis including 9 observational cohort studies and 712,287 participants compared PD risk across antidiabetic drug classes; the study also examined age, sex, and cardiovascular-disease subgroups. [228] Because the evidence was observational, differences between drug classes may reflect confounding by diabetes severity, comorbidity, treatment indication, or healthcare utilization rather than direct neuroprotective or harmful effects of the medications. [228]
Clinically established type 1 diabetes mellitus was independently associated with higher PD risk in a nationwide Korean nested case-control study: adjusted odds ratio 1.42 (95% CI 1.06–1.90) after adjustment for vascular and metabolic comorbidities. [243] This result contrasts with some earlier Mendelian-randomization signals suggesting a protective association between genetic liability to type 1 diabetes and PD, underscoring possible differences between genetic proxies and clinically diagnosed disease. [243]
Cholesterol and low-density lipoprotein cholesterol (LDL-C) are emerging but unresolved epidemiologic factors. A systematic review of longitudinal patient cohorts examined total cholesterol and LDL-C in relation to PD risk and progression, based on the premise that cholesterol is important for neuronal membranes, myelination, and synaptic function. [230] The review emphasizes that peripheral lipid concentrations and central nervous system lipid regulation are not interchangeable, and the direction and clinical meaning of longitudinal associations remain uncertain. [230]
Traumatic brain injury and other environmental exposures
TBI has been investigated as a potential PD risk factor. In a multicenter Mexican cross-sectional study of 443 patients with PD and 525 controls, cumulative TBI history was assessed by structured interview, with TBI defined as head injury involving loss of consciousness or amnesia; the analysis examined sex-related differences. [240] A separate study of older US Veterans evaluated incident PD before and after acute TBI, using a retrospective VHA cohort of adults aged ≥55 years and matched non-TBI comparators, thereby addressing the possibility that the association is bidirectional. [237] These designs support an association hypothesis but cannot by themselves establish that TBI causes PD. [237][240]
A Korean study of early PD assessed whether prior head trauma was associated with motor phenotype and non-motor manifestations. Participants had disease duration ≤5 years and modified Hoehn and Yahr stages 1–3; tremor-dominant, akinetic-rigid, and mixed subtypes were compared. [241] This study addresses phenotypic heterogeneity after diagnosis rather than establishing head trauma as a causal population risk factor. [241]
Prodromal and susceptibility markers
Pure autonomic failure can precede PD, dementia with Lewy bodies, or multiple system atrophy. A systematic review and meta-analysis evaluated phenoconversion rates and predictors, separately and collectively, for these central α-synucleinopathies. [231] Thus, pure autonomic failure should be regarded as a possible prodromal syndrome, not as a conventional exposure that independently causes PD. [231]
Among untreated individuals with prodromal PD, excessive daytime sleepiness was studied as a predictor of transition between tremor-dominant and posterior-instability/gait-disorder motor subtypes. The cohort initially screened 65 participants and followed 38 for 3 years. [232] These findings concern progression and subtype transition, rather than incidence of PD in the general population. [232]
Routine probiotic medication use was examined in a nationwide Japanese nested case-control study using claims data from 2005–April 2025 among adults aged 20–74 years with incident PD or Alzheimer disease. [242] The study evaluated whether prior probiotic use was associated with subsequent neurodegenerative disease, but the supplied evidence does not establish causality or provide the effect estimate. [242]
Vitamin D deficiency has been proposed as a PD-related factor. A Thai randomized study enrolled 60 patients with PD and 60 healthy controls and randomized patients to 2,000 IU/day vitamin D3 or no additional treatment for 12 weeks. [235] This trial primarily evaluated deficiency prevalence and clinical outcomes after diagnosis; it does not establish vitamin D deficiency as a cause of incident PD. [235]
Factors not established as PD incidence risks
The cited trials of GLP-1 receptor agonists, tavapadon, prasinezumab, foslevodopa/foscarbidopa, and focused ultrasound evaluate treatment efficacy, safety, or complications and do not establish population-level PD risk factors. [225][226][227][233][234] Likewise, studies of institutionalization and Parkinson disease dementia address prognosis and diagnostic classification after PD onset rather than disease incidence. [218][229]
| Factor or marker | Current evidence | Interpretation |
|---|---|---|
| Increasing age and population burden | PD prevalence rose in Sweden and France during 2003–2022. [239] | Supports increasing public-health burden; age-specific estimates were not supplied. |
| Diabetes mellitus | Included as a recognized PD risk factor in a network meta-analysis of 9 cohorts/712,287 participants. [228] | Observational associations may be confounded by disease severity and treatment indication. |
| Type 1 diabetes | Adjusted odds ratio 1.42 (95% CI 1.06–1.90) in a Korean nested case-control study. [243] | Association differs from some genetic-proxy findings. |
| Traumatic brain injury | Studied in Mexican, US Veterans, and Korean cohorts. [237][240][241] | Potential association; causality and directionality remain uncertain. |
| Cholesterol/LDL-C | Longitudinal cohort evidence reviewed systematically. [230] | Relationship with risk and progression remains unresolved. |
| Pure autonomic failure | Recognized possible prodrome to PD, DLB, or MSA. [231] | Prodromal syndrome rather than established causal exposure. |
| Probiotic medication use and vitamin D | Investigated in Japanese claims data and a Thai randomized trial, respectively. [235][242] | Neither establishes a causal incidence relationship from the supplied evidence. |
Diagnosis and Workup
- ▸The cited 2026 evidence expands supportive and quantitative assessment but does not validate a single replacement test for expert clinical diagnosis of Parkinson disease. [250]
- ▸Wearable gait, speech, facial, hand-movement, and gait-machine-learning tools are promising for screening, phenotyping, monitoring, or differential diagnosis, but require validation before routine diagnostic use. [245,250,259]
- ▸Olfactory dysfunction, idiopathic REM sleep behavior disorder, excessive daytime sleepiness, and vagus-nerve ultrasound findings may support prodromal or phenotypic research but lack validated individual diagnostic thresholds. [232,248,249,251]
- ▸H. pylori and vitamin D testing may be clinically relevant in selected patients but are not diagnostic criteria for Parkinson disease. [235,246]
- ▸Advanced MRI, dopamine-transporter PET, cognitive testing, polysomnography, and delirium monitoring should be selected according to the clinical question rather than used as universal diagnostic tests. [214,253,254,257,258]
Diagnostic approach
Parkinson disease (PD) remains primarily a clinical diagnosis; the supplied 2026 evidence does not validate a single imaging, laboratory, microbiome, wearable, or machine-learning test as a replacement for expert clinical assessment. This evidence base instead expands the range of potentially useful supportive, prodromal, quantitative, and differential-diagnostic assessments. Machine-learning studies using facial expression, hand-movement, speech, voice, and gait data from general-purpose equipment are aimed at screening, early diagnosis, severity assessment, and staging, but the systematic review identified substantial methodological heterogeneity across 133 studies and should not be interpreted as establishing routine diagnostic accuracy. [250]
The clinical assessment should document the distribution and evolution of parkinsonism, gait and balance impairment, cognition, executive function, autonomic symptoms, sleep symptoms, olfaction, psychiatric symptoms, and functional impact. Quantitative gait testing may add objective characterization: in de novo PD, GAITRite analysis was evaluated alongside striatal dopamine-transporter availability by 18F-FP-CIT PET, brain gray-matter volumetry, and motor and cognitive measures to examine independent dopaminergic and limbic-cognitive contributions to gait impairment. [254] Wearable-device interventions have been studied in 13 randomized trials involving 380 participants and were associated with changes in gait, balance, or motor outcomes, supporting their potential for longitudinal quantification, although this evidence concerns treatment and monitoring rather than diagnostic confirmation. [245]
Supportive and prodromal markers
Olfactory dysfunction is an early and common non-motor feature of PD. A systematic review of 20 MRI studies involving 1,092 patients found reported associations between olfactory impairment and structural changes involving the olfactory sulcus and bulb, cortical gray matter, hippocampus, and related regions, but results varied according to the region of interest and analytic method. Structural MRI therefore remains investigational as an olfactory-linked diagnostic biomarker. [249]
Idiopathic rapid-eye-movement sleep behavior disorder (iRBD) is a recognized prodromal manifestation of α-synucleinopathies. In a PPMI-based analysis of 37 hyposmia-free iRBD patients and 37 matched controls, resting-state functional-connectivity analyses identified altered network organization interpreted as possible early cortical compensation in a body-first PD phenotype. These findings support risk stratification research but do not establish that functional MRI can diagnose PD in an individual with iRBD. [251] Excessive daytime sleepiness may also have prognostic value: among initially screened untreated prodromal patients, 38 underwent three-year annual follow-up to examine transitions between tremor-dominant and posterior-instability/gait-disorder motor subtypes. [232]
Autonomic or enteric-pathway findings are likewise investigational. A meta-analysis evaluated vagus-nerve cross-sectional area by ultrasonography because vagal structural alterations may reflect disease-related neurodegeneration; the study addressed whether vagus-nerve area is reduced in PD compared with controls, but does not establish a diagnostic threshold for clinical use. [248] Gut-directed evidence is therapeutic rather than diagnostic: two systematic reviews evaluated fecal microbiota transplantation (FMT) in randomized trials, with one review including seven randomized controlled trials and both reviews assessing motor, non-motor, and cognitive outcomes. Neither establishes microbiome testing or FMT response as a diagnostic test. [244][256]
Imaging and differential diagnosis
Conventional structural MRI is most appropriately considered when the presentation is atypical or an alternative structural disorder must be excluded; the cited literature does not provide a validated MRI criterion for idiopathic PD. Advanced imaging may support research characterization. In de novo PD, 18F-FPIT PET and MRI gray-matter volumetry were combined with quantitative gait analysis, while a separate retrospective study used multimodal MRI-derived morphometry and glymphatic parameters to predict short-term motor response after subthalamic-nucleus deep-brain stimulation in 155 patients; these findings concern phenotyping or treatment-response prediction rather than diagnosis. [254][257]
Differentiation from progressive supranuclear palsy (PSP) can be difficult early because motor features overlap. In a retrospective study of 34 participants with PSP and 410 with PD, wearable inertial-sensor gait measures were analyzed with machine learning to identify clinically interpretable distinctions. This approach is promising for differential diagnosis but requires external validation before routine adoption. [259]
Associated-condition and safety assessment
Testing should be guided by symptoms and treatment context rather than performed as a universal PD panel. Helicobacter pylori testing is relevant only to the studied subgroup: a double-blind randomized trial enrolled H. pylori-positive adults with PD and compared 14 days of triple eradication therapy with placebo, assessing motor, non-motor, and quality-of-life outcomes at 12 weeks. The trial does not support H. pylori status as a diagnostic criterion for PD. [246] Vitamin D status may be assessed when clinically indicated; a randomized study enrolled 60 patients with PD and 60 healthy controls, defined deficiency as 25(OH)D <20 ng/mL, and tested 2,000 IU/day supplementation for 12 weeks, but this does not establish vitamin D deficiency as diagnostic. [235]
Cognitive and sleep assessment should be incorporated when symptoms suggest impairment, because executive dysfunction, excessive daytime sleepiness, iRBD, delirium, and sleep disorders can complicate assessment. A sham-controlled study of 28 patients used digit-span, trail-making, verbal-fluency, Simon, and stop-signal tasks to measure executive function, illustrating the breadth of targeted testing, but it evaluated transcranial stimulation rather than diagnostic performance. [214] In hospitalized patients, wearable monitoring of activity and sleep has been studied for feasibility and acceptability in detecting delirium, a condition that may overlap clinically with cognitive impairment, hallucinations, and sleep disturbance in PD. [253]C Catathrenia requires attended overnight polysomnography with synchronized audio-video recording for diagnosis and may be mistaken for sleep apnea or parasomnia; it is a sleep differential diagnosis rather than a PD biomarker. [258]C
Interpretation of emerging evidence
Rehabilitation, virtual-reality exercise, MR-guided focused-ultrasound thalamotomy, tavapadon, and device-aided therapy studies provide outcome measures useful for baseline characterization but do not alter the diagnostic definition of PD. [226][247][252][255] Accordingly, emerging digital, imaging, autonomic, olfactory, sleep, and microbiome measures should be reported as supportive or investigational findings, while diagnosis remains anchored to the longitudinal clinical syndrome and exclusion of plausible mimics. [248-250,254,259]
| Modality | Evidence and current role |
|---|---|
| Clinical and functional assessment | Core longitudinal assessment of motor, non-motor, cognitive, sleep, autonomic, and functional features; the cited studies do not replace clinical diagnosis. [214][232][250] |
| Wearables and machine learning | Quantitative gait, balance, activity, sleep, speech, facial, and hand-movement analysis; promising but not yet a standalone diagnostic test. [245][250][253]C[259] |
| MRI and PET | Investigational phenotyping, gait-correlation, and treatment-response prediction; no validated diagnostic threshold is provided. [249][254][257] |
| Olfaction, iRBD, and sleepiness | Supportive prodromal-risk markers; individual predictive thresholds remain unestablished. [232][249][251] |
| Vagus ultrasonography and microbiome testing | Research biomarkers or therapeutic pathways, not established diagnostic investigations. [244][248][256] |
| Targeted laboratory or sleep testing | H. pylori, vitamin D, and polysomnography are indication-based assessments, not PD-confirmatory tests. [235][246][258]C |
Diagnosis and Differential Diagnosis
- ▸The detection of phospho-α-synuclein in skin biopsies is a critical tool for differentiating synucleinopathies (PD, MSA) from tauopathies (PSP).
- ▸31P MR spectroscopy provides a metabolic signature of midbrain energy homeostasis that can discriminate early-stage PD from its mimics.
The diagnosis of Parkinson Disease (PD) remains primarily clinical, centered on the identification of motor features resulting from the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta [98]D[99]D. However, the insidious onset and clinical overlap with other neurodegenerative disorders—specifically 'Parkinson-plus' syndromes—necessitate a rigorous diagnostic workup to differentiate idiopathic PD from mimics such as Multiple System Atrophy (MSA), (PSP), and Vascular (VP) [36][71]D. Recent advancements in molecular biomarkers, such as skin biopsies for phospho-α-synuclein and advanced phosphorus MR spectroscopy, have significantly enhanced diagnostic precision [71]D[74]D.
Management of Parkinson Disease
- ▸Levodopa timing is critical; even brief delays in administration in acute settings like the ED can lead to severe morbidity [28].
- ▸Symmetric Parkinson's disease is a predictor of poorer outcomes for both dopaminergic medication and subthalamic deep brain stimulation [122].
The of Parkinson Disease (PD) requires a multi-modal approach that integrates pharmacological optimization, surgical intervention, and targeted rehabilitation to address both motor and non-motor symptoms (NMS) [124]D. Because PD is a progressive neurodegenerative disorder, treatment must be dynamic, transitioning from symptomatic relief in early stages to complex management of motor fluctuations and cognitive changes in advanced disease [95]D[124]D. ### Step 1: Initial Assessment and Severity Classification Clinicians must first classify the disease phenotype and severity to determine the appropriate intervention path.
Supportive Care and Complication Management
- ▸Physical therapy efficacy is enhanced by cortical priming with intermittent theta-burst stimulation (iTBS).
- ▸Virtual reality (VR) and body weight-supported treadmill training (BWSTT) are superior for gait and balance rehabilitation.
- ▸Transcutaneous auricular vagus nerve stimulation (taVNS) improves both motor scores and non-motor symptoms like sleep.
- ▸Cycling for 40-60 minutes three times weekly may specifically slow the progression of urinary frequency in early PD.
- ▸Expiratory muscle strength training (EMST) is vital for preventing aspiration pneumonia, with mHealth apps improving long-term adherence.
- ▸Palliative care significantly improves quality of life, especially in underserved demographics.
Multidisciplinary Rehabilitation and Physical Therapy
Supportive care in Parkinson's disease (PD) has evolved from a limited evidence base to a robust field with over 240 randomized controlled trials as of 2026 [197]. Physical therapy (PT) remains a cornerstone of management, particularly for addressing the 'capacity-performance gap' in mobility and balance [197]. Recent evidence suggests that the efficacy of PT can be significantly enhanced through cortical priming; specifically, bilateral intermittent theta-burst stimulation (iTBS) over the primary motor cortex (M1) twice daily for two weeks has been shown to provide additional gains in motor function when combined with standard PT [199].
Gait and Balance Interventions
Gait impairments, including freezing of gait (FOG), often persist despite optimal pharmacological management [198]C. Modern interventions increasingly utilize technology to address these challenges:
- Virtual Reality (VR) and Treadmill Training: Systematic reviews indicate that VR protocols (typically 5 to 12 weeks) improve balance, gait speed, and dual-task performance [195]. Combining treadmill training with gamified virtual reality environments (GVRE) and transcranial direct current stimulation (tDCS) may further address motor-cognitive deficits that worsen under cognitive load [198]C. Non-immersive VR (NIVR) using semi-spherical devices has also demonstrated efficacy in improving UPDRS Part III scores and spatiotemporal gait parameters over 12 weeks [200].
- Body Weight-Supported Treadmill Training (BWSTT): This modality remains a high-quality option for mild-to-moderate PD, showing significant improvements in gait rehabilitation [195].
- Voluntary Walking and Specialized Mats: Structured voluntary walking interventions (>3 weeks or >6 sessions) significantly improve velocity, distance, and cadence [196]. Novel tools like the Fisior® sequential square mat, used in a 12-week progressive balance and resistance program, have shown efficacy in improving gait speed and physical performance [203].
- Rebound Therapy: Task-oriented exercises performed on a trampoline (rebound therapy) twice weekly for 6 weeks have proven more effective than stable-surface exercises for improving balance, gait, and knee strength [130].
Neuromodulation for Motor and Non-Motor Symptoms
Non-invasive neuromodulation is emerging as a versatile supportive therapy:
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Meta-analyses and clinical trials confirm that taVNS improves motor function (MDS-UPDRS III), gait parameters, and non-motor symptoms such as sleep and quality of life [111][131]. Neuroimaging suggests taVNS works by decreasing glutamate levels in the striatum and thalamus and enhancing brain connectivity [131].
- Transcranial Direct Current Stimulation (tDCS): When combined with standardized rehabilitation for FOG, anodal tDCS over the pre-motor/motor cortex can enhance the learning of cognitive and sensory cueing strategies, which are often difficult for patients to master due to cognitive load [127].
Exercise Modalities and Doses
Network meta-analyses of 44 RCTs involving 2,273 patients suggest that exercise modality and dose are critical for quality of life (QOL) [140].
- Cycling: In early PD, cycling exercise (three 40-60 minute sessions per week for 24 weeks) has been shown to selectively benefit autonomic symptoms, specifically reducing the progression of urinary frequency [112].
- Exergaming: Universally designed exergame programs are feasible and potentially effective even for patients in advanced stages (Hoehn & Yahr III-V) [128].
- Reactive Training: Home-based, time-constrained reactive training (e.g., visually guided reaching and stepping) can enhance movement speed and reduce reaction times in both upper and lower limbs [129].
Management of Pain and Respiratory Complications
- Pain Management: Chronic pain is a debilitating non-motor symptom. Combining Transcutaneous Electrical Nerve Stimulation (TENS) with a 20-minute exercise program has been investigated for its effects on pain intensity and fatigue [204]. For chronic shoulder pain (subacromial pain syndrome) in PD, ultrasound-guided suprascapular nerve block combined with pulsed radiofrequency (PRF) is effective, with outcomes potentially influenced by the severity of rigidity [205].
- Respiratory Care: Aspiration pneumonia is a leading cause of mortality in PD [63]. Expiratory muscle strength training (EMST) is recommended to improve swallowing and respiratory function. Adherence to long-term EMST can be significantly improved through mHealth interventions, such as the SpiroGym app [63].
Palliative Care and Telerehabilitation
Palliative care interventions have demonstrated significant benefits in improving QOL, particularly for underserved populations (rural, low-income, or minority groups) [201]. To increase accessibility, telerehabilitation (TR) via real-time videoconferencing has been shown to be a feasible method for delivering individualized physiotherapy in early-stage PD, potentially lowering costs and maximizing clinician reach [202]C.
| Intervention | Primary Benefit | Evidence Level |
|---|---|---|
| taVNS | Motor function, gait, and sleep | 1a [111], 1b [131] |
| VR Training | Balance and dual-task performance | 1a [195], 1b [200] |
| iTBS + PT | Enhanced motor function gains | 1b [199] |
| tDCS + Rehab | Improved learning of FOG strategies | 1b [127] |
| mHealth EMST | Respiratory/swallowing adherence | 2b [63] |
Special Populations in Parkinson Disease
- ▸Early-Onset Parkinson Disease (onset 21–50 years) requires a management strategy that prioritizes the delay of motor fluctuations and dyskinesias, which occur more frequently than in late-onset cases.
- ▸Elderly patients with PD have a nearly threefold increased risk of upper-thoracic vertebral fractures, necessitating early bone density screening and aggressive osteoporosis management.
Parkinson disease (PD) exhibits significant clinical heterogeneity, necessitating tailored strategies for specific patient subgroups. While the classic presentation involves older adults, the rising global burden of (EOPD) and the unique complications faced by the very elderly, pregnant patients, and those with specific comorbidities require distinct clinical approaches [46]D[154]D. ### Early-Onset Parkinson Disease (EOPD) EOPD is defined by a symptom onset between the ages of 21 and 50 years [154]D[46]D.
Guidelines and Resources
- ▸Balance dysfunction research requires a multimodal approach including video-oculography and posturography [206].
- ▸Hospitalized PD patients are at high risk due to medication timing errors and unrecognized dysphagia [181, 187].
- ▸Physical therapy is recommended as a mandatory complement to STN-DBS for axial symptoms [179].
- ▸Cerebral small vessel disease burden is significantly higher in PD patients compared to healthy controls and correlates with gait impairment [90].
- ▸GBA1 variant testing requires specialized genetic counseling to communicate the associated risk of PD [170].
- ▸Continuous subcutaneous apomorphine infusion (CSAI) initiation should be tailored to one of five specific patient profiles [207].
Clinical Practice Guidelines and Consensus Roadmaps
Recent international consensus efforts have focused on standardizing the management of Parkinson's disease (PD) across diverse clinical domains. A 2026 consensus roadmap addresses balance dysfunction, emphasizing that postural stability depends on multisensory integration and accurate perception of self-motion [206]. The roadmap advocates for standardized use of video-oculography, vestibular evoked myogenic potentials (VEMPs), and posturography to improve clinical translation [206]. For cognitive disorders, updated best practice guidelines established through a modified Delphi process provide 51 recommendations for the diagnosis and evaluation of cognitive impairment, incorporating both expert and lived-experience perspectives [168].
Management of Non-Motor and Hospitalized Symptoms
Non-motor symptoms significantly impact quality of life and disease progression [169]. The German Society of Neurology's 2025 guidelines provide evidence-based recommendations for managing autonomic failure, pain, and sleep disturbances [169]. Similarly, the Brazilian Academy of Neurology has released comprehensive recommendations for neuropsychiatric symptoms, including depression, anxiety, and psychosis [175].
In the hospital setting, specific risks such as medication timing errors, contraindicated medications, restricted mobility, and dysphagia must be addressed [181]. Expert recommendations for managing dysphagia in hospitalized patients emphasize that swallowing difficulties may be present without overt clinical signs, necessitating interdisciplinary collaboration between neurology, nursing, and speech-language pathology to prevent delays in medication administration [187]D. Furthermore, a systematic review of bone health guidelines highlights that PD patients face a high fracture risk due to low bone mineral density and frequent falls, requiring proactive osteoporosis management [174].
Advanced Therapies and Specialized Care Models
For patients with motor fluctuations, continuous subcutaneous apomorphine infusion (CSAI) is a key intervention. French practical guidelines now define five distinct patient profiles to guide the target dose and subsequent adjustment of oral treatments [207]. However, access to such device-aided therapies remains inconsistent; for instance, experts in Poland have identified significant gaps in the reimbursement of apomorphine and intestinal gel infusions [210].
Specialized care models, such as the Parkinson’s day-clinic, have been introduced to bridge the gap between ambulatory and inpatient care for advanced PD [208]. For patients treated with subthalamic deep brain stimulation (STN-DBS), a Delphi consensus study strongly recommends physical therapy to address dopamine-resistant symptoms like postural instability and freezing of gait [179]. Additionally, the use of safinamide for motor fluctuations has been standardized through regional expert consensus to optimize its clinical application [209].
Diagnostic Biomarkers and Emerging Technologies
Diagnostic accuracy is being refined through the study of cerebrospinal fluid (CSF) biomarkers and neuroimaging. Network meta-analyses suggest that CSF biomarkers can help differentiate PD from atypical parkinsonian syndromes, though their role as first-line tools is still being established [177]. Neuroimaging research indicates that PD patients exhibit a greater burden of cerebral small vessel disease (CSVD)—including white matter hyperintensities and microbleeds—which correlates with worse motor and gait scores [90]. Meta-analyses of resting-state fMRI have also identified altered regional spontaneous brain activity in PD [176].
To improve the reliability of clinical assessments, computer vision-based automated systems are being developed to correct rater discrepancies in MDS-UPDRS Part III scoring [211]. Furthermore, clinical consensus has been sought to define the meaningful motor progression threshold on the MDS-UPDRS Part III in the OFF medication state to better track disease evolution [212].
Travel, Genetics, and Palliative Care
Specific guidance has been developed for long-distance air travel, which may temporarily worsen motor and non-motor states due to dehydration, hypoxia, and jet lag [191]D. In genetics, consensus guidance for GBA1 variants—the most common genetic risk factor for PD—emphasizes the importance of standardized counseling regarding PD risk [170]. Finally, there is an increasing shift toward early palliative care, with research identifying indicators for timely access and the need to overcome organizational barriers to provide holistic support for patients and caregivers [178].
| Domain | Key Recommendation | Reference |
|---|---|---|
| Cognition | 51 evidence-based recommendations for diagnosis and management | [168] |
| Hospital Care | Avoid contraindicated medications and prioritize medication timing | [181] |
| Bone Health | Systematic screening for osteoporosis due to high fracture risk | [174] |
| Air Travel | Personalized pre-travel planning to mitigate hypoxia and jet lag effects | [191]D |
| DBS | Integration of physical therapy to treat dopamine-resistant gait issues | [179] |
References
- [1]
Gregson CL, Armstrong DJ, Avgerinou C et al.. “The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.” Archives of osteoporosis (2025). PMID: 40921943 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Xavier D, Felizardo V, Ferreira B et al.. “Voice analysis in Parkinson's disease - a systematic literature review.” Artificial intelligence in medicine (2025). PMID: 40132400 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Bradley M, O'Loughlin S, Donlon E et al.. “Determining Falls Risk in People with Parkinson's Disease Using Wearable Sensors: A Systematic Review.” Sensors (Basel, Switzerland) (2025). PMID: 40648326 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Moss Lopes PR, Westphal Filho FL, Mendes Filho FSM et al.. “Prevalence of Supine Hypertension in Alpha-Synucleinopathies: A Systematic Review and Meta-Analysis.” Movement disorders clinical practice (2025). PMID: 40406920 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Pecoraro PM, Marsili L, Espay AJ et al.. “Computer Vision Technologies in Movement Disorders: A Systematic Review.” Movement disorders clinical practice (2025). PMID: 40326633 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Sharma P, Singh SM, Mehta S et al.. “High-definition transcranial direct current stimulation for depressive and other non-motor symptoms in Parkinson's disease: a randomised, sham-controlled, cross-over study.” East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2026). PMID: 41916935 ↗
L1bRCTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Differential Diagnosis, Management - [7]
Cole-Hunter T, Antic S, Lim YH et al.. “Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41772748 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [8]
Davydow DS, Okun MS, Pontone GM. “Potential Risk Factors for Psychosis in Parkinson's Disease: A Review of Cohort and Case-Control Studies.” Journal of geriatric psychiatry and neurology (2025). PMID: 39925085 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [9]
Gilat M, Nonnekes J, Factor SA et al.. “An updated definition of freezing of gait.” Nature reviews. Neurology (2026). PMID: 41513745 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Guidelines and Resources - [10]
Rigon L, Poplawska-Domaszewicz K, Metta V et al.. “The challenges with the identification of Parkinson's disease subtypes.” Expert review of neurotherapeutics (2026). PMID: 41474600 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [11]
Bougea A. “Staging and markers in Parkinson's disease and Lewy body disorders: narrative review.” Therapeutic advances in chronic disease (2025). PMID: 41146744 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [12]
Ma H, Zhu Y, Zhao X et al.. “Pyroptosis: inflammatory cell death mechanism and its pathological roles in neurological diseases and injuries.” Apoptosis : an international journal on programmed cell death (2025). PMID: 40813542 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [13]
Factor SA, Weinshenker D, McKay JL. “A possible pathway to freezing of gait in Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973500 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Höglinger GU, Lang AE. “SynNeurGe: The road ahead for a biological definition of Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973492 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bendetowicz D, Planche V, Bezard E et al.. “Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease.” Journal of Parkinson's disease (2025). PMID: 39973487 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [16]
Tinazzi M, Geroin C, Siciliano M et al.. “Pain and fatigue in Parkinson's disease: advances in diagnosis and management.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 39937423 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [17]
Soto C, Mollenhauer B, Hansson O et al.. “Toward a biological definition of neuronal and glial synucleinopathies.” Nature medicine (2025). PMID: 39885358 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [18]
Lesley R, Simpson J, Dale M et al.. “Predictors of Informal Caregiver Burden in Parkinson's Disease: A Systematic Review.” Western journal of nursing research (2025). PMID: 40138495 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [19]
Cataldo E, de Oliveira Aguiar AG, Silva LAS. “A Methodological Review of Voice Acoustic Parameters, with Emphasis on Vocal Tremor: Definitions, Computation, and Software Tools.” Journal of voice : official journal of the Voice Foundation (2026). PMID: 41951462 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [20]
Fan SP, Okuzumi A, Chen PS et al.. “Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.” Journal of the Formosan Medical Association = Taiwan yi zhi (2025). PMID: 41353001 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [21]
Calzetti S, Calzetti G. “The nosology of tardive parkinsonism.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 41130187 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [22]
Subramanian I, Ricciardi L, Schrag A et al.. “A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.” Movement disorders clinical practice (2026). PMID: 41084417 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [23]
Brenlla C, Lazaro-Hernandez C, Fernandez M et al.. “Biomarkers of neurodegenerative parkinsonisms: From current clinical to future biological definitions - literature review and our experience.” Neurologia i neurochirurgia polska (2025). PMID: 40207871 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [24]
Markiewicz M, Madetko-Alster N, Alster P. “Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice.” Frontiers in neurology (2024). PMID: 39634776 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [25]
Stinson SE, Shadrin AA, Rahman Z et al.. “Distinct metabolic signatures of Alzheimer's and Parkinson's disease revealed through genetic overlap.” EBioMedicine (2026). PMID: 41966729 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [26]
Ekert JO, Patel V, Zhou X et al.. “Enhancing 7T MRI for deep brain stimulation with deep-learning based image reconstruction and dynamic parallel transmission.” NeuroImage. Clinical (2026). PMID: 41962172 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Dinter E, Margraff JL, Schniewind I et al.. “CSF alpha-Synuclein Seed Amplification Assay results in routine clinically collected samples.” Journal of Parkinson's disease (2026). PMID: 41944207 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Elder NM, Lash EM, Tomkins-Tinch C. “An Underrecognized Problem: Missed and Delayed Carbidopa-Levodopa Administration in Emergency Department Patients With Parkinson's Disease.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41910596 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Management, Special Populations - [29]
Barbosa RP, Bastos P, Béreau M et al.. “Is being asymmetric a bad thing? Insights from a longitudinal observational study on STN-DBS Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41887013 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [30]
Park D, Lee WR, Bang M et al.. “Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality.” Journal of pain research (2026). PMID: 41710284 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [31]
Liu R, Zhang S, Xiao Y et al.. “The Effects of Digital Health Interventions on Motor Symptoms, Nonmotor Symptoms, and Quality of Life in Patients With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of medical Internet research (2026). PMID: 41818739 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors - [32]
Hemeda S, Elmadani M, Merzah M et al.. “Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41578833 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [33]
Yang D, Nepal G, Ojha R et al.. “Association between dairy consumption and Parkinson's disease: A systematic review and meta-analysis.” Public health (2026). PMID: 41544344 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [34]
Bang CS, Hasanuzzaman M, Lee JJ et al.. “Association between Helicobacter pylori infection and Parkinson's disease: A systematic review and meta-analysis.” European journal of clinical investigation (2026). PMID: 41527373 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [35]
Barer Y, Ast T, Chodick G et al.. “Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.” Parkinsonism & related disorders (2026). PMID: 41468681 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [36]
Chen X, Barclay NL, Pineda-Moncusí M et al.. “Secular trends of incidence and prevalence of Parkinsonism subtypes: a cohort study in the United Kingdom.” European journal of public health (2026). PMID: 41954920 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations - [37]
Bae Y, Song C, Kim S et al.. “Risk of somatoform and sleep-related disorders in Parkinson's disease: A nationwide matched cohort study.” Sleep medicine (2026). PMID: 41812492 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [38]
Kamo H, Remz M, Mehta TR et al.. “Five-year risk of cardiovascular events and falling in Parkinson's disease with orthostatic hypotension: A nationwide cohort study.” Parkinsonism & related disorders (2026). PMID: 41637898 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [39]
Davoodi L, Frouzanian M, Soleymani E et al.. “Investigating the prevalence of Toxoplasma gondii infection in Parkinson's disease patients and its association with disease severity: a case-control study.” BMC infectious diseases (2026). PMID: 41526839 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations - [40]
Kang MS, Jung YT, Kim S et al.. “Upper-thoracic predominance and non-vertebral fracture burden in Parkinson's disease: A matched Case-Control study.” Parkinsonism & related disorders (2026). PMID: 41468680 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations - [41]
Huang X, Cheng Q, Xie Y et al.. “Chinese patent medicine in the treatment of Parkinson's disease: A systematic review and network meta-analysis.” Complementary therapies in clinical practice (2026). PMID: 41505870 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [42]
Cheng B, Cheng S, Wei W et al.. “Residential green space, natural environment, domestic garden, and the risk of Parkinson's disease: A prospective cohort study.” Neurobiology of disease (2026). PMID: 41759830 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [43]
Gusmão NA, Mateus APM, Oliveira VB et al.. “Parkinson's disease and Porphyromonas gingivalis levels: a case-control study.” Journal of applied oral science : revista FOB (2026). PMID: 41880470 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors - [44]
Gomes de Luna JR, Lima DP, Gomes VC et al.. “Sarcopenia, body composition, physical performance, and clinical features in Parkinson's disease: a cross-sectional comparative study.” Frontiers in endocrinology (2026). PMID: 41924518 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [45]
Zhou L, Guan M, Zhang B et al.. “Depression in Parkinson's disease: prevalence and impact on oculomotor features.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41895089 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [46]
Shen Q, Zheng F, Dong Y et al.. “Global, regional, and national burden of Early-onset Parkinson's disease: A comprehensive analysis and forecast, 1990-2021.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41876889 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations - [47]
Jian X, Yu P, Zhang Y et al.. “Large-scale profiling of blood microbial signatures in patients with Parkinson's disease and its association with disease progression: a cross-sectional study.” EBioMedicine (2026). PMID: 41864063 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [48]
Step K, Ndong Sima CAA, Grant S et al.. “Polygenic risk scores and Parkinson's disease in South Africa advancing ancestry informed disease prediction.” PLoS genetics (2026). PMID: 41801886 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Ahn SH, Kim DH, Park J et al.. “Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality: A Competing Risk Analysis Approach.” Neurology (2026). PMID: 41740083 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
Tang X, Cui H, Cui H. “Orchestrating the Parkinson's disease microenvironment in 3D for pathogenesis study and therapeutic development.” Biofabrication (2026). PMID: 41719587 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [51]
Arias-Carrión O. “Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.” Medical sciences (Basel, Switzerland) (2026). PMID: 41718119 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [52]
Onrubia-Márquez M, Garcia MM, Navas F et al.. “MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson's Behavioral Dysfunction in Mice.” International journal of nanomedicine (2026). PMID: 41710371 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [53]
Li S, Chen S, Yu X et al.. “Scoping review of AI-driven wearable technologies for rehabilitation and functional assessment in Parkinson's disease: a protocol.” BMJ open (2026). PMID: 41692525 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [54]
Vakhshoori M, Bondariyan N, Jones J et al.. “The impact of cardiovascular disease on Parkinson's disease: Findings from the PPMI study.” Parkinsonism & related disorders (2026). PMID: 41643580 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [55]
Li G, Li G. “The impact of diabetes mellitus in prodromal Parkinson's disease.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41639475 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [56]
Sun M, Wang X, Lu Z et al.. “GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.” Diabetes, obesity & metabolism (2026). PMID: 41582696 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [57]
Di Luca DG, de Havenon A, Prabhune A et al.. “Temporal trends and risk factors of hospital readmission following deep brain stimulation for Parkinson disease.” Parkinsonism & related disorders (2026). PMID: 41579428 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [58]
Mammen JR, Reddy V, Lerner A et al.. “Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.” Journal of neurology (2026). PMID: 41563488 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [59]
Park CW, Choi Y, Sun Y et al.. “Visuospatial dysfunction indicates an increased risk of rapid dementia conversion in Parkinson's disease.” Alzheimer's & dementia : the journal of the Alzheimer's Association (2026). PMID: 41540811 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [60]
Chen W, Du M, Liu M et al.. “Co-occurrence patterns and related risk factors of dementia and Parkinson's disease among older adults across 204 countries and territories: a spatial correspondence and systematic analysis.” BMC medicine (2026). PMID: 41540403 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [61]
Wu J, Zang W, Fang M et al.. “Effects of Wearable Devices on Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Within the International Classification of Functioning, Disability, and Health Framework.” Journal of medical Internet research (2026). PMID: 41849761 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup - [62]
Alla D, Shah D, Ramsundar R et al.. “Efficacy and Safety of Deferiprone for Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical neuropharmacology (Unknown). PMID: 41790482 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup - [63]
Srp M, Hoskovcova M, Lagnerova R et al.. “Enhancing Adherence to Home-Based Expiratory Muscle Strength Training in Parkinson Disease: Randomized Controlled Trial of an mHealth Intervention.” Journal of medical Internet research (2026). PMID: 41812147 ↗
L1bRCTCited in: Diagnosis and Workup, Management, Supportive Care and Complication Management - [64]
Raza H, Nizam B, Padaniya A et al.. “Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.” Brain and behavior (2026). PMID: 41880197 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [65]
Mohammed I, Nankya Y, Hong UT et al.. “The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes.” Amino acids (2026). PMID: 41874704 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [66]
Boffino CC, Holzhacker TY, Silva SMA et al.. “Effects of galvanic vestibular stimulation on motor control in patients with Parkinson's disease: study protocol.” Arquivos de neuro-psiquiatria (2026). PMID: 41759503 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management - [67]
Brito SAF, Scianni AA, Silveira BMF et al.. “High-intensity respiratory muscle training improves maximal respiratory pressures, breathing endurance, dyspnoea and exercise capacity in people with Parkinson's disease: a randomised trial.” Journal of physiotherapy (2026). PMID: 41933952 ↗
L1bRCTCited in: Diagnosis and Workup, Differential Diagnosis, Management, Supportive Care and Complication Management - [68]
Coskun K, Turan GB. “The Effects of Color Therapy on Fatigue, Depression, and Quality of Life in Parkinson's Patients: A Randomized Controlled Trial.” Brain and behavior (2026). PMID: 41888497 ↗
L1bRCTCited in: Diagnosis and Workup, Management - [69]
Baggen RJ, Van Bladel A, Prins MR et al.. “Visual perturbation training to reduce visual dependency in Parkinson's disease: A randomized controlled trial.” PloS one (2026). PMID: 41770816 ↗
L1bRCTCited in: Diagnosis and Workup, Management - [70]
Huang H, Zhu R, Zheng Y et al.. “Effect evaluation of the positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) positive psychological intervention model in patients with Parkinson's disease.” Neuropsychology (2026). PMID: 41770127 ↗
L1bRCTCited in: Diagnosis and Workup - [71]
Lonczewski S, Bader V, Ortmann L et al.. “A Novel 3D Semi-Automated Full Quantification Technique for Detection of Intraneural Phospho-α-Synuclein in Skin Biopsies.” European journal of neurology (2026). PMID: 41995607 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations - [72]
Sowalsky KL, Okun MS, Terza M et al.. “Regular Metronome, Fractal Metronome, and Music for Parkinson Gait.” JAMA network open (2026). PMID: 41989783 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Management - [73]
Kim YJ, Choi SI, Yang H et al.. “Insole-Derived Plantar Pressure Variability Reveals Dual-Task Gait Differences in Early-Stage Parkinson's Disease.” IEEE journal of translational engineering in health and medicine (2026). PMID: 41970941 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations - [74]
Yu Q, Zhang Y, Huang P et al.. “Midbrain Energy Homeostasis Biomarker for Differential Diagnosis of Early-Stage Parkinson Disease: A 1H and 31P MRI Study.” Radiology (2026). PMID: 41944724 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis - [75]
Zhu S, Yi W, Feng Y et al.. “Decomposed Transfer Entropy for EEG Brain Networks: Parkinson's Disease and Dopaminergic Modulation.” IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society (2026). PMID: 41941809 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis - [76]
Akram SW, K C. “Enhancing Parkinson's Disease Staging: An Integrative Deep Learning Framework for Multimodal Feature Selection.” Journal of molecular neuroscience : MN (2026). PMID: 41910849 ↗
L5OTHERCited in: Diagnosis and Workup - [77]
Lin J, Lee PY, Tran KKN et al.. “Detailed Outer Retinal Assessment in Parkinson's Disease Using Directional OCT.” Investigative ophthalmology & visual science (2026). PMID: 41910525 ↗
L5OTHERCited in: Diagnosis and Workup - [78]
Noor MS, Jadapalli J, Walker HC et al.. “Localizing beta synchronous neurons in the STN using directional DBS recordings and patient-specific biophysical models.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41881902 ↗
L5OTHERCited in: Diagnosis and Workup, Management - [79]
Boebinger SE, Payne AM, Xiao J et al.. “Cortically Mediated Muscle Responses to Balance Perturbations Increase with Perturbation Magnitude in Older Adults with and without Parkinson's Disease.” eNeuro (2026). PMID: 41871956 ↗
L5OTHERCited in: Diagnosis and Workup - [80]
Li Z, Yang R, Cui X et al.. “Orthostatic blood pressure trajectories characterize heterogeneous disease progression in Parkinson's disease.” Journal of neurology (2026). PMID: 41870682 ↗
L5OTHERCited in: Diagnosis and Workup - [81]
Niemi KJ, Jaakkola E, Myller EM et al.. “Striatal Dopamine Transporter and Rest Tremor in Parkinson Disease: A Clinical Validation.” Neurology (2026). PMID: 41855450 ↗
L5OTHERCited in: Diagnosis and Workup - [82]
Wang Q, Lv M, Zhou X et al.. “Association of choroid plexus volume with MRI indices of DTI-derived parameters and perivascular spaces in patients with neurodegenerative diseases.” European journal of radiology (2026). PMID: 41849872 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [83]
Morcillo-Martínez L, Sanz-Mármol M, Romanos-Navarrete AI et al.. “Effects of a level-based immersive virtual reality physical therapy program on static and dynamic balance in Parkinson's disease: Protocol for a randomized controlled trial.” PloS one (2026). PMID: 41838745 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management, Special Populations - [84]
Wei X, Tian Y, Lu Q et al.. “Dynamic Reconfiguration of Cognitive Networks and Recovery From Microlesion Effects in Parkinson's Disease: Insights From a Longitudinal fNIRS Study.” CNS neuroscience & therapeutics (2026). PMID: 41834033 ↗
L5OTHERCited in: Diagnosis and Workup, Management - [85]
Gravel P, Gallezot JD, Fontaine K et al.. “Variance reduction with synaptic density imaging in Parkinson's disease using direct-4D PET image reconstruction.” Physics in medicine and biology (2026). PMID: 41825140 ↗
L5OTHERCited in: Diagnosis and Workup - [86]
Mezzini A, Kumar S, Sharrad S et al.. “The Topographical, Sensory, and Temporal Characteristics of Pain in Parkinson's Disease: A Cross-Sectional Survey.” Pain practice : the official journal of World Institute of Pain (2026). PMID: 41814463 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [87]
Kassubek J, Höglinger GU, Zůza A et al.. “Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.” Journal of neurology (2026). PMID: 41811373 ↗
L5OTHERCited in: Diagnosis and Workup - [88]
Jiang H, Chen G, Ma J et al.. “Precise estimation of tissue microstructure with hybrid graph transformer.” Artificial intelligence in medicine (2026). PMID: 41806520 ↗
L5OTHERCited in: Diagnosis and Workup - [89]
Mîndreanu R, Chiș IC, Sevastre-Berghian A et al.. “N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.” International journal of molecular sciences (2026). PMID: 41977262 ↗
L2aSR_OBSCited in: Differential Diagnosis - [90]
Del Papa DF, Herman J, Kunju AT et al.. “Neurovascular Unit Dysfunction and Cerebral Small Vessel Disease in Parkinson Disease: A Systematic Review and a Meta Analysis.” Neurology (2026). PMID: 41955557 ↗
L2aSR_OBSCited in: Differential Diagnosis, Guidelines and Resources - [91]
Hu S, Lei J, You HJ. “Exercise for Non-Motor Symptoms of Parkinson's Disease: An Evidence-Based Review of Clinical Trials, Dosing Considerations, and Mechanistic Insights.” Neural plasticity (2026). PMID: 41918452 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management, Supportive Care and Complication Management - [92]
de Ronde EM, Birnie E, Rijpma A et al.. “Individualised stimlation parameters in deep brain stimulation for Parkinson's disease based on disease phenotype and brain connectivity: protocol for a randomised feasibility study in a tertiary care centre (iDBS trial).” BMJ open (2026). PMID: 41974545 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management - [93]
Zhu Y, Zhao L, Li Y et al.. “Disruption of Synaptic Vesicle Trafficking in Alzheimer's and Parkinson's Disease: Mechanisms and Therapeutic Implication.” International journal of molecular sciences (2026). PMID: 41977275 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [94]
Musarò D, Greco M, Lanza M et al.. “Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models and Translational Evidence.” International journal of molecular sciences (2026). PMID: 41977181 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [95]
Almeida V, Herz DM, Blech J et al.. “Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.” Translational psychiatry (2026). PMID: 41963290 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management - [96]
Ramanan S, Johnson GVW. “A Bioinformatic Analysis of BAG Protein Interactors and Pathways in Alzheimer's and Parkinson's Disease.” Journal of molecular neuroscience : MN (2026). PMID: 41925793 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [97]
Yin X, Wang C, Lin W et al.. “Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.” International journal of nanomedicine (2026). PMID: 41907367 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management - [98]
Ozkaya KS, Browning KN. “The Brain-Gut Axis in Parkinson's Disease Pathology.” Comprehensive Physiology (2026). PMID: 41905903 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [99]
Aslan FS, Barut B, Ozturk S et al.. “Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives.” ACS chemical neuroscience (2026). PMID: 41904982 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [100]
Davis A, Casmedes IY, Burton MD. “Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.” International journal of molecular sciences (2026). PMID: 41898672 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [101]
Rojas Romero CJ, Guerrero Y. “Singing-Based Interventions for Treating Hypokinetic Dysarthria in Parkinson's Disease: A Systematic Review.” Journal of music therapy (2026). PMID: 41990042 ↗
L2aSR_OBSCited in: Differential Diagnosis, Management - [102]
Garanin AA, Aydumova OY, Rubanenko AO et al.. “[Speech signal acoustic analysis in the diagnosis of neurological and mental diseases: a systematic review and meta-analysis].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026). PMID: 41984552 ↗
L2aSR_OBSCited in: Differential Diagnosis - [103]
Jin J, Jiang Y, Zhou Y et al.. “AI-Enabled Flexible Sensing Ecosystems for Parkinson's Disease: Advancing Digital Biomarkers and Closed-Loop Interventions.” Sensors (Basel, Switzerland) (2026). PMID: 41977856 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [104]
Singhal M, Grannie C, Burnette M et al.. “Freezing of Gait in Parkinson's Disease: A Scoping Review on the Path Towards Real-Time Therapies.” Sensors (Basel, Switzerland) (2026). PMID: 41977827 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [105]
Shi WQ, Zhuang JH, Zhang QH et al.. “Synthesis and Biological Evaluation of RBG Derivatives as Nrf2 Activators for the Treatment of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977502 ↗
L5OTHERCited in: Differential Diagnosis - [106]
Toledano-Pinedo M, Porro-Pérez A, Schäker-Hübner L et al.. “Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977320 ↗
L5OTHERCited in: Differential Diagnosis - [107]
Yang JC, Situ J, Troutman R et al.. “A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson's disease.” Human molecular genetics (2026). PMID: 41955304 ↗
L5OTHERCited in: Differential Diagnosis - [108]
Yang D, Xu J, Zhu Y et al.. “The genetic associations of DNAJC family members with Parkinson's disease: comprehensive evidence from burden analysis and Mendelian randomization.” Human genetics (2026). PMID: 41951985 ↗
L5OTHERCited in: Differential Diagnosis - [109]
Gowied HG, El-Mezayen NS, Afify EA. “Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.” Life sciences (2026). PMID: 41936814 ↗
L5OTHERCited in: Differential Diagnosis - [110]
Ahumada-Montalva P, Muñoz-Carvajal F, Bórquez-Macaya S et al.. “TMBIM6 enhances dopaminergic neuron survival by modulating the IRE1a pathway in Parkinson's disease.” Cell death & disease (2026). PMID: 41932887 ↗
L5OTHERCited in: Differential Diagnosis - [111]
Liu C, Jin Y, Lin H et al.. “Effects of transcutaneous auricular vagus nerve stimulation on motor and gait performance in Parkinson's disease: a meta-analysis of randomized controlled trials.” Journal of neurology (2026). PMID: 41805933 ↗
L1aSR_MA_RCTCited in: Management, Supportive Care and Complication Management - [112]
Jun JS, Kang N, Park K et al.. “Cycling exercise for autonomic symptoms in early Parkinson's disease.” Autonomic neuroscience : basic & clinical (2026). PMID: 41740291 ↗
L1bRCTCited in: Management, Supportive Care and Complication Management - [113]
Fidan C. “Technologies used in Parkinson's disease: a meta-analysis of their effect on health-related quality of life.” Journal of neurology (2026). PMID: 41817821 ↗
L2aSR_OBSCited in: Management - [114]
Zhang X, Zheng L, Li Y et al.. “Efficacy of rTMS and TBS on the motor symptoms in Parkinson's disease: a network meta-analysis.” Journal of neurology (2026). PMID: 41817817 ↗
L2aSR_OBSCited in: Management - [115]
Senthilkumar S, S M, Rizvi MF et al.. “Deep brain stimulation beyond Motor control: A systematic review and meta-analysis of sleep outcomes in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41702753 ↗
L2aSR_OBSCited in: Management - [116]
van der Linden C, Berger T, Dembek TA et al.. “Tractography-guided versus clinical contact selection for deep brain stimulation in tremor - A prospective clinical trial.” Brain stimulation (2026). PMID: 41740836 ↗
L2bTRIAL_NONRANDOMCited in: Management - [117]
Zhang R, Feng R, Wang J et al.. “Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial.” Signal transduction and targeted therapy (2026). PMID: 41826284 ↗
L1bRCTCited in: Management - [118]
Ferrara PE, Della Casa E, Calciano R et al.. “Effects of Focal Muscle Vibration on Static and Dynamic Balance in Patients with Parkinson's Disease: Preliminary Results of a Retrospective Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752699 ↗
L2bCOHORTCited in: Management - [119]
Hu W, Li Y, Yang A et al.. “Research progress on employing medicinal plants and their active compounds to target autophagic pathways for Parkinson's disease therapy.” Journal of ethnopharmacology (2026). PMID: 41895540 ↗
L2aSR_OBSCited in: Management - [120]
Pinheiro RSA, Silva Júnior HBD, Guimarães BB et al.. “Effects of Transcranial Direct Current Stimulation on Speech and Voice Changes in Parkinson's Disease: a Systematic Review with Meta-Analysis.” CoDAS (2026). PMID: 41779498 ↗
L2aSR_OBSCited in: Management - [121]
Busot D, Yang H, Sawmiller D et al.. “The Progress of Active Immunotherapy for Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41828418 ↗
L5REVIEW_NARRATIVECited in: Management - [122]
Jost ST, Atwani C, Loehrer PA et al.. “Patients with symmetric Parkinson's disease do poorly with subthalamic stimulation.” Journal of neurology, neurosurgery, and psychiatry (2026). PMID: 41781214 ↗
L5OTHERCited in: Management - [123]
Li J, Liu T, Wei J. “Exercise as Chronotherapy: Regulating Circadian Rhythms to Alleviate Symptoms in Parkinson's Disease.” ACS chemical neuroscience (2026). PMID: 41766127 ↗
L5REVIEW_NARRATIVECited in: Management - [124]
Rajyasree A, Balamurugan J. “"Every day is a battle against Parkinson's"-a qualitative study on older adults at the long-term care facilities in Chennai.” Frontiers in public health (2026). PMID: 41756082 ↗
L5OTHERCited in: Management, Special Populations - [125]
Qiu S, Wei Y, Gao C et al.. “Effects of combined transcranial direct current stimulation and gait training in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.” Systematic reviews (2025). PMID: 41053827 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [126]
Lima JL, Inacio PA, Sá Filho A et al.. “Effectiveness of virtual reality rehabilitation with exergames on functional rehabilitation in Parkinson's disease: a systematic review of chronic randomized controlled trials.” Expert review of neurotherapeutics (2025). PMID: 40963232 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [127]
Madrid J, Batzianouli E, Rutz D et al.. “Can transcranial Direct Current Stimulation enhance the efficacy of a rehabilitative intervention for the treatment of Freezing of Gait in Parkinson's disease? A double-blind, randomized controlled study.” Journal of Parkinson's disease (2026). PMID: 41637203 ↗
L1bRCTCited in: Supportive Care and Complication Management - [128]
Matsushita W, Nagaki K, Takashi N et al.. “Feasibility and potential effectiveness of an exergame program for people with moderate to advanced Parkinson's disease: A pilot randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41637155 ↗
L1bRCTCited in: Supportive Care and Complication Management - [129]
Villamil-Cabello E, Molinero-Martín E, Luque-Casado A et al.. “Home-Based time-constrained reactive training enhances movement speed in upper and lower limbs in Parkinson's disease: A randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41615860 ↗
L1bRCTCited in: Supportive Care and Complication Management - [130]
Eldemir S, Polat EA, Gokdogan CM et al.. “The effect of rebound therapy in Parkinson's disease: A single-blinded randomized controlled trial.” Gait & posture (2026). PMID: 41592453 ↗
L1bRCTCited in: Supportive Care and Complication Management, Special Populations - [131]
Wang R, Liu M, Liu Q et al.. “Home-based transcutaneous auricular vagus nerve stimulation (taVNS) improves motor and non-motor symptoms by improving autonomic and brain functions in patients with Parkinson's disease: A randomized clinical trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41549029 ↗
L1bRCTCited in: Supportive Care and Complication Management - [132]
Kalva-Filho CA, Zampier VC, Orcioli-Silva D et al.. “Inter-effort recovery hypoxia did not mitigate acute treadmill effects in people with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41389475 ↗
L1bRCTCited in: Supportive Care and Complication Management - [133]
Rascol O, Ory-Magne F, Meissner WG et al.. “Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41316871 ↗
L1bRCTCited in: Supportive Care and Complication Management - [134]
da Conceição NR, Vitório R, Morya E et al.. “Effect of Dynamic Balance Training Combined with Different Intensities of Cerebellar Transcranial Direct Current Stimulation in People with Parkinson's Disease: a Randomized Clinical Trial.” Cerebellum (London, England) (2025). PMID: 41239034 ↗
L1bRCTCited in: Supportive Care and Complication Management - [135]
Topal A, Durmaz Çelik N, Ayık B et al.. “Effect of a Wearable Sensor-Based Posture Correction Brace on Static Balance and Posture in Parkinson's Disease.” American journal of physical medicine & rehabilitation (2026). PMID: 41082253 ↗
L1bRCTCited in: Supportive Care and Complication Management - [136]
Thanakamchokchai J, Ajjimaporn A, Richards J et al.. “High-frequency rTMS and home-based exercise in individuals with Parkinson's disease: A double-blind randomized controlled trial.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 40934835 ↗
L1bRCTCited in: Supportive Care and Complication Management - [137]
Hernandez-Martinez J, Branco BHM, Cid-Calfucura I et al.. “Exergaming Compared to Conventional Physical Exercise Interventions on Health Status in Older People with Parkinson's Disease: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.” Medicina (Kaunas, Lithuania) (2025). PMID: 41303837 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [138]
Mollinedo-Cardalda I, Monge-Pereira E, Pereira-Pedro KP et al.. “Acute effects of an aerobic dual task on processing speed and attention in Parkinson's disease: a randomised controlled trial study.” Journal of bodywork and movement therapies (2025). PMID: 41316559 ↗
L1bRCTCited in: Supportive Care and Complication Management - [139]
Li Y, Liu Y, Lin Z et al.. “Aerobic exercise modulates plasma oxidized lipid metabolites and neurotransmitters in Parkinson's disease motor subtypes.” Brain research (2025). PMID: 41205731 ↗
L1bRCTCited in: Supportive Care and Complication Management - [140]
Zeng B, Wang H, Chen J et al.. “Optimal exercise modalities and doses for improving quality of life in patients with Parkinson's disease: a network meta-analysis and dose-response study.” Journal of neurology (2026). PMID: 41656425 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [141]
Yan HL, Li MM. “Effects of exercise modalities on cognitive function and depression in patients with Parkinson's disease: A systematic review and network meta-analysis.” Geriatric nursing (New York, N.Y.) (2025). PMID: 41129905 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [142]
Han C, Zhang H, Wang Q et al.. “Physical exercise and inflammation in Parkinson's disease: a review.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41085917 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [143]
Decaix T, Bonnin C, Götze K et al.. “Benefits of physical activity on cognitive function in patients with neurocognitive disorders: A systematic review.” The Journal of frailty & aging (2025). PMID: 40911419 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [144]
Xiao C, Zhou F. “Yi Jin Jing Exercise Program Improves in Cognition, Sleep and Functional Mobility for Mild and Moderate Parkinson 's Disease: A Randomized Controlled Trial.” Experimental aging research (2026). PMID: 41388828 ↗
L1bRCTCited in: Supportive Care and Complication Management - [145]
Fukuchi CA, Moreno VC, Kalva-Filho CA et al.. “Combining automated mechanical peripheral stimulation and treadmill exercise for gait rehabilitation in Parkinson's disease: A randomized controlled trial.” Clinical biomechanics (Bristol, Avon) (2026). PMID: 41337903 ↗
L1bRCTCited in: Supportive Care and Complication Management - [146]
González-García P, Heredia-Rizo AM, Garrido-Bueno A et al.. “Multi-Session whole body vibration program on Parkinson's disease symptoms: Systematic review and meta-analysis.” Journal of bodywork and movement therapies (2025). PMID: 41316661 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [147]
Domínguez-Pera I, Lucena-Anton D, Estebanez-Perez MJ et al.. “Efficacy of transcranial direct current stimulation combined with gait training in patients with Parkinson's disease: Systematic review and meta-analysis.” CNS spectrums (2025). PMID: 41065007 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [148]
Taveira RS, Vasconcellos LS, Bezerra CF et al.. “Telerehabilitation for people with Parkinson's disease: protocol of a randomised clinical trial of mixed methods.” BMJ open (2025). PMID: 41320221 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [149]
Tufft A, Neilens H, Marsden J et al.. “Efficacy of peroneal nerve functional electrical stimulation (FES) for the reduction of bradykinesia in Parkinson's disease: an assessor-blinded randomised controlled trial (STEPS II)-study protocol.” BMJ open (2025). PMID: 40912703 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [150]
Greenland JC, Dresser K, Cutting E et al.. “Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.” The Lancet. Neurology (2026). PMID: 41389828 ↗
L1bRCTCited in: Special Populations - [151]
Song T, Xiang L, Liu Y et al.. “Survival and related factors in patients with Parkinson's disease: a multicenter prospective cohort study in China.” Journal of neurology (2026). PMID: 41507598 ↗
L2bCOHORTCited in: Special Populations - [152]
Fleet JL, Carter B, Cadarette SM et al.. “Fracture incidence and osteoporosis treatment in Parkinson's disease: a population-based cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41369770 ↗
L2bCOHORTCited in: Special Populations - [153]
Erfmann K, Hirschwald J, Hofacker J et al.. “Characteristics of Swallowing Function in People with Parkinson's Disease: A Scoping Review.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41508417 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [154]
Hickman J, Tsai A, Fullard M et al.. “Early-Onset Parkinson's Disease: Unique Features and Management Approaches.” Current neurology and neuroscience reports (2025). PMID: 41410819 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [155]
Calzada García M, Ayala A, Navarta Sánchez MV et al.. “[Impact of a community-based multisectoral intervention on the health of individuals with parkinson's disease and their family caregivers].” Semergen (2026). PMID: 41707402 ↗
L1bRCTCited in: Special Populations - [156]
Machane D, Shaji MS, Borchman D et al.. “Meibum Lipid Saturation Related to Dry Eye, Age, and Sex Using Nuclear Magnetic Resonance Spectroscopy.” Investigative ophthalmology & visual science (2026). PMID: 41910524 ↗
L5OTHERCited in: Special Populations - [157]
Sriram D, Pourzinal D, Bailey DX et al.. “Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 41834361 ↗
L5OTHERCited in: Special Populations, Guidelines and Resources - [158]
Hatakeyama S, Miki Y, Tanaka MT et al.. “Cerebrospinal fluid HOMER1 and NPTX2 as candidate signatures in early-stage multiple system atrophy-parkinsonism.” Journal of the neurological sciences (2026). PMID: 41780424 ↗
L5OTHERCited in: Special Populations - [159]
Lian J, Fan Z, Petrazzini BO et al.. “Subtyping Alzheimer's disease and Parkinson's disease using longitudinal electronic health records.” Nature aging (2026). PMID: 41748957 ↗
L5OTHERCited in: Special Populations - [160]
Falk L, Brunius C, Crnic Bojkovic T et al.. “A data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism using 11C-PE2I PET.” NeuroImage. Clinical (2026). PMID: 41719754 ↗
L5OTHERCited in: Special Populations - [161]
Bolsewig K, Bellomo G, Hok-A-Hin YS et al.. “A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.” Nature medicine (2026). PMID: 41699128 ↗
L5OTHERCited in: Special Populations - [162]
Anis S, Kundrick A, Callegari Piccinin C et al.. “Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.” Parkinsonism & related disorders (2026). PMID: 41691977 ↗
L5OTHERCited in: Special Populations - [163]
Ou C, Chen B, Yu H et al.. “Association between the triglyceride-glucose frailty index and Parkinson's disease in middle-aged and older adults: a comparative cross-national analysis of NHANES and CHARLS.” Parkinsonism & related disorders (2026). PMID: 41691976 ↗
L5OTHERCited in: Special Populations - [164]
Kim D, Tjaden K, Stipancic KL et al.. “Variable Speech Cueing Effects in Talkers With Parkinson's Disease.” American journal of speech-language pathology (2026). PMID: 41666082 ↗
L5OTHERCited in: Special Populations - [165]
Gunawardana CW, Burke PGR, Ignatavicius A et al.. “Comparing phenotypic features between Parkinson's disease dementia and dementia with Lewy bodies.” Journal of neurology (2026). PMID: 41665721 ↗
L5OTHERCited in: Special Populations - [166]
Singovski S, Harlé L, Zerbit J et al.. “Continuous subcutaneous apomorphine infusion to improve comfort in advanced degenerative Parkinsonian syndrome patients: a retrospective descriptive study in a home-based setting.” Parkinsonism & related disorders (2026). PMID: 41653908 ↗
L5OTHERCited in: Special Populations - [167]
Hobson R, Levy SHS, Singal CMS et al.. “Clonal CD8+ T cells populate the leptomeninges and coordinate with immune cells in human degenerative brain diseases.” Nature immunology (2026). PMID: 41593242 ↗
L5OTHERCited in: Special Populations - [168]
Pourzinal D, Brooks D, Sriram D et al.. “Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.” Age and ageing (2026). PMID: 41870152 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Fanciulli A, Sixel-Döring F, Buhmann C et al.. “Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2025). PMID: 39751950 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Vieira SRL, Mezabrovschi R, Toffoli M et al.. “Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.” Movement disorders : official journal of the Movement Disorder Society (2024). PMID: 39258449 ↗
L1cGUIDELINECited in: Guidelines and Resources - [171]
Witt K, Levin J, van Eimeren T et al.. “Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2024). PMID: 39046524 ↗
L1cGUIDELINECited in: Guidelines and Resources - [172]
Tönges L, Buhmann C, Eggers C et al.. “Guideline "Parkinson's disease" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care.” Journal of neurology (2024). PMID: 38969876 ↗
L1cGUIDELINECited in: Guidelines and Resources - [173]
Walter U, Loewenbrück KF, Dodel R et al.. “Systematic review-based guideline "Parkinson's disease" of the German Society of Neurology: diagnostic use of transcranial sonography.” Journal of neurology (2024). PMID: 38963440 ↗
L1cGUIDELINECited in: Guidelines and Resources - [174]
Ó Breasail M, Singh KP, Lithander FE et al.. “Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines.” Movement disorders clinical practice (2025). PMID: 39704021 ↗
L1cGUIDELINECited in: Guidelines and Resources - [175]
Maia DP, Cury RG, Brandão PRP et al.. “Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology - non-motor symptoms.” Arquivos de neuro-psiquiatria (2025). PMID: 39993447 ↗
L1cGUIDELINECited in: Guidelines and Resources - [176]
Liao J, Wang L, Liu R et al.. “Altered regional spontaneous brain activity in Parkinson's disease: a meta-analysis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41579202 ↗
L2aSR_OBSCited in: Guidelines and Resources - [177]
Li S, Yang C, Wu J et al.. “Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis.” Journal of neurology (2025). PMID: 41324773 ↗
L2aSR_OBSCited in: Guidelines and Resources - [178]
Garon M, Weck C, Leta V et al.. “Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review.” Journal of Parkinson's disease (2025). PMID: 40320755 ↗
L2aSR_OBSCited in: Guidelines and Resources - [179]
Guidetti M, Marceglia S, Bocci T et al.. “Is physical therapy recommended for people with parkinson's disease treated with subthalamic deep brain stimulation? a delphi consensus study.” Journal of neuroengineering and rehabilitation (2025). PMID: 40211348 ↗
L2aSR_OBSCited in: Guidelines and Resources - [180]
Rosado-Martins F, Santos B, Costa CM et al.. “Vestibular Dysfunction in Parkinson's Disease: A Systematic Review of Signs and Symptoms.” Movement disorders clinical practice (2026). PMID: 40854008 ↗
L2aSR_OBSCited in: Guidelines and Resources - [181]
Veilleux Carpentier A, Malaty IA, LeWitt PA et al.. “A Systematic Review of the Parkinson's Foundation Hospital Care Recommendations.” Movement disorders clinical practice (2026). PMID: 40736219 ↗
L2aSR_OBSCited in: Guidelines and Resources - [182]
Lima DP, Gomes VC, Luna JRG et al.. “Assessment of sarcopenia tools as predictors of falls in patients with mild to moderate Parkinson's Disease: A cohort study.” Clinics (Sao Paulo, Brazil) (2025). PMID: 40972508 ↗
L2bCOHORTCited in: Guidelines and Resources - [183]
Cordillet S, Drapier S, Leh F et al.. “Detecting Freezing of Gait in Parkinson Disease Using Multiple Wearable Sensors Sets During Various Walking Tasks Relative to Medication Conditions (DetectFoG): Protocol for a Prospective Cohort Study.” JMIR research protocols (2025). PMID: 39913915 ↗
L2bTRIAL_NONRANDOMCited in: Guidelines and Resources - [184]
Gülke E, Lewis SJG. “What is new in Freezing of Gait?” Journal of neurology (2026). PMID: 41865085 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [185]
Chen K, Hao W, Ji Y et al.. “Two novel iron metabolism-related genes identified as diagnostic indicators in substantia nigra of patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41643581 ↗
L5OTHERCited in: Guidelines and Resources - [186]
Anis S, Clark PA, Shaffer S et al.. “Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41577516 ↗
L5OTHERCited in: Guidelines and Resources - [187]
Safarpour D, Brooks A, Smiley A et al.. “Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41490026 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [188]
Pedrosa AJ, Molter JN, Brito de Almeida L et al.. “A modified Delphi study of post-operative management for subthalamic deep brain stimulation in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41217788 ↗
L5OTHERCited in: Guidelines and Resources - [189]
Rosenbohm A, Nguyen-Younossi N, Kassubek J. “Parkinson's disease-associated camptocormia: biopsy-confirmed focal myositis and treatment options.” Journal of neurology (2025). PMID: 41131373 ↗
L5OTHERCited in: Guidelines and Resources - [190]
Houston E, Boyd S, Iyer V et al.. “The need for developing consensus-based guidelines in assessing Parkinson's disease laterality.” Parkinsonism & related disorders (2025). PMID: 41039696 ↗
L5OTHERCited in: Guidelines and Resources - [191]
Poplawska-Domaszewicz K, Kaasinen V, van der Plas AA et al.. “Management of neuropsychiatric, motor and non-motor symptoms in Parkinson´s disease after long distance air travel: a consensus view.” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40986033 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [192]
Sajin V, Goodall M, Macerollo A. “Camptocormia in Parkinson's disease: state of the art and future directions.” Journal of neurology (2025). PMID: 40975851 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [193]
Wang S, Zhou F, Fang X et al.. “Evidence-based summary of the prevention and management of constipation in patients with Parkinson's disease.” Geriatric nursing (New York, N.Y.) (2025). PMID: 40834448 ↗
L5OTHERCited in: Guidelines and Resources - [194]
Middlebrooks EH, Bot M, Patriat R et al.. “Multi-institutional recommendations on the use of 7T MRI in deep brain stimulation.” Journal of neurosurgery (2025). PMID: 40614283 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [195]
Battaglion GGS, Boni FDS, Zhang K et al.. “Virtual Reality and Body Weight-Supported Treadmill Training in Gait Rehabilitation for Parkinson Disease: A Systematic Review.” American journal of physical medicine & rehabilitation (2026). PMID: 41811930 ↗
L1aCited in: Supportive Care and Complication Management - [196]
Kloster CT, Bonde-Jensen F, Langeskov-Christensen M et al.. “Parkinson's Disease and Voluntary Walking Interventions-A Systematic Review and Meta-analysis.” Archives of physical medicine and rehabilitation (2026). PMID: 41628826 ↗
L1aCited in: Supportive Care and Complication Management - [197]
Ellis T. “Movement Through Time: The Evolution of Treatment for People With Parkinson Disease.” Journal of neurologic physical therapy : JNPT (2026). PMID: 42313921 ↗
L1bCited in: Supportive Care and Complication Management - [198]
Bosch-Barceló P, Tersa-Miralles C, Martínez-Navarro O et al.. “A treadmill training program in a gamified virtual reality environment combined with transcranial direct current stimulation in Parkinson's Disease: Preliminary results of a mixed methods randomized controlled trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42277373 ↗
L4Cited in: Supportive Care and Complication Management - [199]
Zhang HY, Hou TT, Chen KK et al.. “Intermittent theta-burst stimulation to enhance physical therapy in Parkinson's disease: The STEP-PD randomized trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41926908 ↗
L1bCited in: Supportive Care and Complication Management - [200]
Lim S, Park J, Kim J et al.. “Clinical efficacy of a non-immersive virtual reality-based balance training device in improving balance and gait in Parkinson's disease; A randomized controlled trial.” Parkinsonism & related disorders (2026). PMID: 41855753 ↗
L1bCited in: Supportive Care and Complication Management - [201]
Yilmaz S, Aslam S, Sillau S et al.. “Bridging the gap: Evaluating a community-based palliative care intervention for underserved patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41812391 ↗
L1bCited in: Supportive Care and Complication Management - [202]
Skelly R, Lindop F, Gordon AL et al.. “Telerehabilitation for early-stage Parkinson's disease: A randomized controlled feasibility trial of individualised real-time physiotherapy delivered via a videoconference platform.” Journal of Parkinson's disease (2026). PMID: 41719152 ↗
L4Cited in: Supportive Care and Complication Management - [203]
Alegre-Tamariz J, Ramirez C, Runzer-Colmenares FM et al.. “Effects of a gait training program with the Fisior® sequential square mat on balance and gait in patients with Parkinson's disease: a randomized clinical trial.” BMC complementary medicine and therapies (2026). PMID: 41555326 ↗
L1bCited in: Supportive Care and Complication Management - [204]
Garcez PA, DeJesus BM, Oliveira LR et al.. “Effect of transcutaneous electrical nerve stimulation associated to exercise for pain in Parkinson's disease: a randomized crossover clinical trial.” Pain management (2026). PMID: 42083446 ↗
L1bCited in: Supportive Care and Complication Management - [205]
Karabacak A, Gezer Karabacak T, Özen Barut B. “Efficacy of Suprascapular Nerve Block and Pulsed Radiofrequency for Chronic Shoulder Pain in Parkinson's Disease.” Pain research & management (2026). PMID: 42213538 ↗
L2bCited in: Supportive Care and Complication Management - [206]
Shaikh AG, Antoniades C, Arshad Q et al.. “Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.” Current opinion in neurology (2026). PMID: 42307076 ↗
L1cCited in: Guidelines and Resources - [207]
Ory Magne F, Drapier S, Marques AR et al.. “A delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations.” Parkinsonism & related disorders (2025). PMID: 40413152 ↗
L1cCited in: Guidelines and Resources - [208]
Buhmann C, Kalbe E, Claus I et al.. “Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40299066 ↗
L1cCited in: Guidelines and Resources - [209]
Rodrigues AM, Costa C, Gago M et al.. “Expert perspectives on the use of safinamide for Parkinson's disease in Portugal: insights from a Portuguese Delphi Consensus.” Journal of comparative effectiveness research (2025). PMID: 40474741 ↗
L1cCited in: Guidelines and Resources - [210]
Popławska-Domaszewicz K, Siuda J, Rudzińska-Bar M et al.. “Challenges of equitable access to device-aided therapies for advanced Parkinson's Disease in Poland - expert consensus and treatment recommendations.” Neurologia i neurochirurgia polska (2024). PMID: 39737586 ↗
L1cCited in: Guidelines and Resources - [211]
Xu J, Xu X, Guo X et al.. “Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation.” Journal of Parkinson's disease (2025). PMID: 39973505 ↗
L2bCited in: Guidelines and Resources - [212]
Trundell D, Davies EW, Barrett L et al.. “Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.” Journal of Parkinson's disease (2025). PMID: 39973477 ↗
L2bCited in: Guidelines and Resources - [213]
Rayapuraju A, Reed PU, Liu J et al.. “Meditation and breathwork on anxiety in Parkinson's disease: A pilot randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 42563479 ↗
L4Cited in: Definition, Synonyms, and Classification - [214]
Dong K, Zhao Y, Zhu X et al.. “Theta tACS Over the Medial Frontal Cortex Modulates Executive Function in Parkinson's Disease: A Randomized, Sham-Controlled Study.” CNS neuroscience & therapeutics (2026). PMID: 42499269 ↗
L1bCited in: Definition, Synonyms, and Classification - [215]
Esper CD, Hogan KN, Abeysekara P et al.. “Case Definitions and Data Sources for NNCSS Parkinson Disease Surveillance: A Systematic Review.” JAMA network open (2026). PMID: 42258214 ↗
L2aCited in: Definition, Synonyms, and Classification - [216]
Delva A, Fereshtehnejad SM, Vo A et al.. “Evolution of Motor and Nonmotor Characteristics in an Idiopathic/Isolated REM Sleep Behavior Disorder Cohort.” Neurology (2025). PMID: 40921020 ↗
L4Cited in: Definition, Synonyms, and Classification - [217]
Venkatesan S, Zakare-Fagbamila RT, Sriram S et al.. “Management Patterns in Deep Brain Stimulator Hardware Infection: Is Hardware Sparing Feasible?” Stereotactic and functional neurosurgery (2026). PMID: 42545957 ↗
L4Cited in: Definition, Synonyms, and Classification - [218]
Mana M, Mana J, Stofanikova P et al.. “Evaluation of diagnostic concordance between algorithms for Parkinson's disease dementia.” Journal of Parkinson's disease (2026). PMID: 42277619 ↗
L3bCited in: Definition, Synonyms, and Classification - [219]
Douros A, Cui Y, Dell'Aniello S et al.. “Influenza Immunization at Midlife and the Risk of Parkinson Disease.” JAMA network open (2025). PMID: 41348356 ↗
L3bCited in: Definition, Synonyms, and Classification - [220]
Chernicky J, Dworetsky A, Grossen S et al.. “Towards precision functional brain network mapping in Parkinson's disease.” NeuroImage. Clinical (2025). PMID: 41496387 ↗
L3bCited in: Definition, Synonyms, and Classification - [221]
Zülke AE, Luppa M, Sander C et al.. “Prevalence and associated factors of subjective cognitive decline (SCD Plus): a cross-sectional analysis of three population-based European cohorts.” Alzheimer's research & therapy (2026). PMID: 42174744 ↗
L3bCited in: Definition, Synonyms, and Classification - [222]
Liu Y, Chen M, Chen P et al.. “Machine learning-based stratification of mild cognitive impairment in Parkinson's disease: a multicenter cross-sectional analysis.” BMC medical informatics and decision making (2025). PMID: 41094519 ↗
L3bCited in: Definition, Synonyms, and Classification - [223]
Sarasso E, Pelosin E, Ruotolo I et al.. “Exploring the fatigue phenomenon in individuals with Parkinson's disease: an Italian multicenter cross-sectional study.” Acta neurologica Belgica (2026). PMID: 42065803 ↗
L3bCited in: Definition, Synonyms, and Classification - [224]
Croteau D, Tobenkin A, Chan V et al.. “Corneal edema: an underrecognized safety risk of amantadine.” Journal of neurology (2026). PMID: 42000941 ↗
L4Cited in: Definition, Synonyms, and Classification - [225]
Mendonça MF, Interaminense AC, do R Barros GST et al.. “Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trials.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42105060 ↗
L1aCited in: Epidemiology and Risk Factors - [226]
Fernandez HH, Bhatia P, Cloud L et al.. “Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.” The Lancet. Neurology (2026). PMID: 42456682 ↗
L1bCited in: Epidemiology and Risk Factors - [227]
Nikolcheva T, Pagano G, Anzures-Cabrera J et al.. “Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.” Lancet (London, England) (2026). PMID: 42208564 ↗
L2bCited in: Epidemiology and Risk Factors - [228]
Lee SH, Rho Y, Lee S et al.. “Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.” Journal of global health (2026). PMID: 42626880 ↗
L2aCited in: Epidemiology and Risk Factors - [229]
Li Y, McLernon DJ, Lawson RA et al.. “Personalised prediction of institutionalisation in Parkinson's: prognostic factor identification and model development and validation using IPD meta-analysis.” Parkinsonism & related disorders (2026). PMID: 42335823 ↗
L2aCited in: Epidemiology and Risk Factors - [230]
Lumi R, Tartakovskaja J, Ye L et al.. “When bad turns good: a systematic review on cholesterol and LDL in longitudinal patient cohorts with Parkinson's disease.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42126660 ↗
L2aCited in: Epidemiology and Risk Factors - [231]
Virameteekul S, Bonini I, Campese N et al.. “Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-Analysis.” JAMA neurology (2026). PMID: 42081229 ↗
L2aCited in: Epidemiology and Risk Factors - [232]
Liang K, Ouyang Y, Luo M et al.. “Relationship between excessive daytime sleepiness and motor subtype transition in untreated prodromal Parkinson's disease: a cohort study.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42530693 ↗
L2bCited in: Epidemiology and Risk Factors - [233]
Campo-Caballero D, Rodriguez-Antiguedad J, Puig-Davi A et al.. “Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study.” European journal of neurology (2026). PMID: 42405633 ↗
L2bCited in: Epidemiology and Risk Factors - [234]
Dalvi A, Eisenberg HM, Wu P et al.. “Safety and efficacy of staged, bilateral magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson's disease: a prospective, multicentre, single-arm trial.” The Lancet. Neurology (2026). PMID: 42309086 ↗
L2bCited in: Epidemiology and Risk Factors - [235]
Anamnart C, Kitjarak R. “Effect of vitamin D supplementation on clinical outcomes of patients with Parkinson disease: A randomized controlled study.” Medicine (2026). PMID: 42499083 ↗
L1bCited in: Epidemiology and Risk Factors - [236]
Pilateris I, Bostanjopoulou S. “"Brain-First" vs. "Body-First" PD: Definitions and Implications in Everyday Clinical Practice: A Systematic Review.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356129 ↗
L2aCited in: Epidemiology and Risk Factors - [237]
Peltz C, Albrecht J, Bahorik AL et al.. “Neurologic Diagnoses Before and After Traumatic Brain Injury: A Retrospective Cohort Study of Older Veterans.” Neurology (2026). PMID: 42308449 ↗
L3bCited in: Epidemiology and Risk Factors - [238]
Wu LY, du Toit T, Georgiades T et al.. “Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.” JAMA neurology (2026). PMID: 42258190 ↗
L3bCited in: Epidemiology and Risk Factors - [239]
Guinebretiere O, Yang F, Wei D et al.. “Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).” Neurology (2026). PMID: 42247653 ↗
L3bCited in: Epidemiology and Risk Factors - [240]
Lázaro-Figueroa A, Garza-Flores S, Reyes-Pérez P et al.. “Cumulative traumatic brain injury as a predictor of Parkinson's disease with sex-related differences.” Parkinsonism & related disorders (2026). PMID: 42128459 ↗
L3bCited in: Epidemiology and Risk Factors - [241]
Lee HL, Choi SM, Cho SH et al.. “Relationship Between Head Trauma History and Motor Subtype in Early Parkinson's Disease.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356071 ↗
L2bCited in: Epidemiology and Risk Factors - [242]
Ihara Y, Miyaue N, Ihara M et al.. “Association of probiotic medication use with incident Parkinson disease and alzheimer disease: a nationwide nested case-control study.” Journal of neurology (2026). PMID: 42223673 ↗
L3bCited in: Epidemiology and Risk Factors - [243]
Yu MH, Hong N, Jeong SH. “Type 1 diabetes and risk of Parkinson's disease: A nationwide nested case-control study.” Parkinsonism & related disorders (2026). PMID: 42214114 ↗
L3bCited in: Epidemiology and Risk Factors - [244]
Siam AM, Moubarak ES, Mahmoud NE et al.. “Efficacy and safety of fecal microbiota transplantation in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42533232 ↗
L1aCited in: Diagnosis and Workup - [245]
Zhong Q, Liu D, Xu Y et al.. “Effects of wearable devices on gait, balance, and motor function in people with Parkinson's disease: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42528864 ↗
L1aCited in: Diagnosis and Workup - [246]
Vishwas G, Kakkar AK, Mehta S et al.. “Helicobacter pylori eradication therapy and clinical outcomes in Parkinson's disease: a double-blind randomized placebo-controlled trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42579018 ↗
L1bCited in: Diagnosis and Workup - [247]
Björkdahl A, Khalif A, Gustafsson M et al.. “Outcomes of rehabilitation following device-aided therapy start in parkinson's disease: a randomized controlled trial.” Journal of rehabilitation medicine (2026). PMID: 42549611 ↗
L1bCited in: Diagnosis and Workup - [248]
Sijben LCJ, van Kuijk SMJ, Jahanshahi A et al.. “Ultrasonography demonstrates vagus nerve atrophy in Parkinson's disease: a meta-analysis.” Journal of neurology (2026). PMID: 42458102 ↗
L2aCited in: Diagnosis and Workup - [249]
Alikhani Y, Zolfaghari A, Shahkarami F et al.. “Associations between olfactory dysfunction and structural MRI findings in Parkinson's disease: a systematic review.” Brain imaging and behavior (2026). PMID: 42423844 ↗
L2aCited in: Diagnosis and Workup - [250]
Moshkova AA, Novikova AO, Polguev MI et al.. “Machine learning-based detection of Parkinson's disease from facial expressions, hand movements, speech, and gait with general-purpose equipment: a systematic review.” International journal of medical informatics (2026). PMID: 42418971 ↗
L2aCited in: Diagnosis and Workup - [251]
Yang Y, Zhou J, Liu Y. “Resting-state functional connectivity reveals cortical compensatory reorganization in idiopathic REM sleep behavior disorder without hyposmia.” Sleep medicine (2026). PMID: 42531839 ↗
L2bCited in: Diagnosis and Workup - [252]
Pistoia F, Salfi F, Arrigoni F et al.. “Clinical outcomes at 6 months after MRgFUS thalamotomy in Parkinson's disease: a large longitudinal cohort study.” Journal of neurology (2026). PMID: 42503072 ↗
L2bCited in: Diagnosis and Workup - [253]
Bate GL, Gerakios F, Yarnall AJ et al.. “Using Wearable Devices to Monitor Activity and Sleep in Inpatients With Parkinson Disease With and Without Delirium: Feasibility and Acceptability Study.” Journal of medical Internet research (2026). PMID: 42490546 ↗
L4Cited in: Diagnosis and Workup - [254]
Kim SW, Lee MJ, Kim JW et al.. “Dual Dopaminergic and Limbic-Cognitive Contributions to Gait Parameters in De Novo Parkinson Disease.” Neurology (2026). PMID: 42430674 ↗
L2bCited in: Diagnosis and Workup - [255]
Zhang H, Yuan X. “The Improvement Effects of Virtual Reality-Assisted Exercise Training on Motor and Psychiatric Symptoms in Patients With Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.” Actas espanolas de psiquiatria (2026). PMID: 42633503 ↗
L1aCited in: Diagnosis and Workup - [256]
Liang B, Zou J, Mao X et al.. “Systematic Review and Meta-Analysis of the Efficacy of Fecal Microbiota Transplantation in Parkinson's Disease: An Exploration Based on UPDRS and Cognitive Scores.” Revista de neurologia (2026). PMID: 42411731 ↗
L1aCited in: Diagnosis and Workup - [257]
Wang Y, Zhang X, Yu W et al.. “Multimodal Neuroimaging-Based Machine Learning Models Leveraging Cerebral Morphometry and Glymphatic Parameters Predict Short-Term Post-Programming STN-DBS Motor Response in Parkinson's Disease.” CNS neuroscience & therapeutics (2026). PMID: 42631338 ↗
L3bCited in: Diagnosis and Workup - [258]
Lopes L, Marques Rodrigues D, Costa T. “Clinical insights into catathrenia: A real-world analysis from a tertiary sleep center.” Pulmonology (2026). PMID: 42609118 ↗
L4Cited in: Diagnosis and Workup - [259]
Sadeghi M, Barouti E, Lyons KE et al.. “Wearable gait analysis for differentiating progressive supranuclear palsy and Parkinson's disease: Clinically interpretable digital biomarkers using machine learning.” Gait & posture (2026). PMID: 42561739 ↗
L3bCited in: Diagnosis and Workup